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ABSTRACT 
UEV1A and MMS2 are two human genes whose proteins share greater than ninety 
percent sequence identity.  Both Uev1A and Mms2 are ubiquitin-conjugating enzyme 
variants (Uev) that lack the active cystine residue required for the ubiquitin conjugation 
reaction.  They work with the ubiquitin-conjugating enzyme Ubc13 to create Lys63-
linked polyubiquitin chains which have recently been found to cause cellular signals not 
involving target protein degradation.  Only the Mms2-Ubc13 complex functions in DNA 
repair in mammalian cells.  In contrast, only the Uev1A-Ubc13 complex is involved in 
TRAF2- and TRAF6-mediated NF-κB activation by ubiquitinating NEMO/IKKγ.  
UEV1B is a splice variant of UEV1A containing different N-terminal coding sequences 
and its cellular function is currently unknown. 
The NF-κB signaling pathway has been regarded as a primary pro-survival and 
anti-apoptotic response.  UEV1A expression is positively correlated to tumor formation, 
suggesting that it plays a role in tumorigenesis.  Furthermore, experimental 
overexpression of UEV1A alone is sufficient to activate NF-κB, which is reversible upon 
suppression of UEV1A expression by RNA interference.  Overexpression of UEV1A also 
protects cells from stress-induced apoptosis and confers a growth advantage under serum-
deprived conditions.  These observations collectively support UEV1A as a candidate 
proto-oncogene. 
The objective of this research was to obtain monoclonal antibodies (Mabs) 
capable of recognizing Uev1, but not Mms2.  This is a challenging task given very few 
possible epitopes that may distinguish the two proteins.  The four sequences unique to 
Uev1A are located in the 30 a.a. N terminal region, the single substitution at a.a. 104,  the 
14 a.a. core region from a.a. 116-129 (7/14 variable) and the C-terminus at a.a. 167-169. 
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Hybridoma cells were produced vis á vis fusions of B cells from Uev1A-
immunized mice with FO myeloma cells lacking the ability to produce immunoglobulin.  
The hybridoma cells were screened using enzyme immunoassays (EIAs) for reactivity 
with Uev1A and Mms2.  Ascities fluid was produced for five Mabs named LN1, LN2, 
LN2A, LN2B and LN3.  EIA and Western blotting of Uev1A-deletion constructs 
revealed that Mab LN1 binds specifically to amino acids (a.a.) 10-30 of the unique 
Uev1A N-terminal sequence, that Mabs LN2, LN2A and LN2B bind specifically to the 
unique a.a. 110-130 region of Uev1A, and that Mab LN3 binds specifically to a.a. 30-44 
of Uev1A common to Mms2. 
Competition analysis of unconjugated Mabs versus horse radish peroxidase 
(HRP)-conjugated Mabs for binding to Uev1A permitted epitope mapping for the five 
Mabs.  The results indicate that Mabs LN1 and LN3 inhibit each other from binding to 
their distinct sequences which are spatially adjacent.  Mabs LN2 and LN2B inhibit each 
other, but not Mab LN2A.  Additionally, Mab LN2A is unable to inhibit Mabs LN2 or 
LN2B.  In summary, Mabs have been aquired to three catergories which were originally 
desired: one to the unique N-terminus (Mab LN1), three to the unique core sequence 
(Mabs LN2, LN2B and LN2A), and one to the same region Ubc13 binds to Uev1A and 
Mms2 (Mab LN3).  The potential applications of these Mabs are discussed. 
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CHAPTER ONE 
LYS63-LINKED UBIQUITINATION AND CANCER 
  
 Ubiquitin (Ub) is one of the most conserved proteins found in all eukaryotic 
organisms.  It exists as a free cellular monomer or it can be covalently modified in 
monomers or chains onto target intracellular proteins (Hershko, 1998).  The 76 amino 
acid (a.a.) Ub polypeptide is critical for many cellular processes such as stress responses, 
cell cycle progression, oncongenesis and antigen presentation (Hofmann and Pickart, 
1999).  Ubiquitination, the attachment of Ub to a target protein, requires the formation of 
an isopeptide bond between the C-terminal Gly76 on Ub and a Lys residue on the target 
protein via a series of steps (Hochstrasser, 1996). 
In this ubiquintination process, Ub is first activated by an Ub-activating enzyme 
(Uba) in the presence of adenosine 5'-triphosphate (ATP), forming a high-energy Uba-Ub 
thiolester bond.  The activated Ub is then transferred from Uba to a specific thiol of an 
Ub-conjugating enzyme (Ubc) to form an Ubc-Ub thiolester.  The Ub of Ubc-Ub is 
further transferred to the target protein either alone or with a Ub ligase (Ubl).  The Ub 
surface Lys residues serve as the substrates for other Ub proteins to bind and form Lys-
linked Ub chains (Chau et al., 1989).  Ub has seven surface Lys residues, creating the 
potential for seven distinct types of chains, at least five of which have been observed in 
vitro or in vivo (Volk et al., 2005).  It has become clear that the signaling properties of Ub 
depend on the topology of the linakage in which the chains are constructed.  Of the five 
Ub linkages observed in vitro or in vivo, only two linkages have been well studied.  The 
well established Gly76-Lys48-linked polyubiquitin chains signal for target proteins to be 
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transported to the 26S proteasome for degradation (Hershko and Ciechanover, 1992; 
Hochstrasser, 1996; Hoege et al., 2002; Hofmann and Pickart, 1999).  Alternatively, 
proteins can also be ubiquitinated through the non-canonical Gly76-Lys63-linkage, which 
in recent years has shown to regulate the function of diverse proteins in a nonproteolytic 
manner (Hofmann and Pickart, 1999).  In fact, Gly76-Lys63-linked chains have been 
implicated in DNA damage tolerance, mitotic checkpoint pathways and Nuclear factor 
kappa B (NF-κB) activation (Andersen et al., 2005; Bothos et al., 2003; Broomfield et al., 
1998). 
 
1.1  Lys63-linked polyubiquitin chains and cellular signaling 
To date, Ubc13 is the only known Ubc enzyme capable of catalyzing the Lys63-
linked polyubiquitination reaction, which also requires a ubiquitin conjugating enzyme 
variant (Uev) as a co-factor (Hofmann and Pickart, 1999; McKenna et al., 2001).  A Uev 
is defined as a protein that resembles Ubc in structure and a.a. sequence, but does not 
contain a Cys residue in the active site, rendering the protein catalytically inactive 
(Broomfield et al., 1998; Sancho et al., 1998).  Ubc13 has a conserved Ubc family 
catalytic domain, which contains an active site Cys residue, allowing it to conjugate Ub 
(Hofmann and Pickart, 1999).  Regulation of Ubc13 activity depends on which Uevs are 
assisting with the formation of the chain (Andersen et al., 2005).  Neither Ubc13 nor Uev 
alone are able to promote polyubiquitin chains (Hofmann and Pickart, 1999). 
Ubc13 creates Lys63-linked polyubiquitin chains with the Uevs Mms2 and 
Uev1A in the DNA damage tolerance and NF-κB signaling processes, respectively.  
Ubc13 physically interacts with Mms2 (Hofmann and Pickart, 1999) to promote error-
free DNA damage tolerance (Broomfield et al., 1998) by polyubiquitination of the 
proliferating cell nuclear antigen (PCNA) via Lys63-linked chains (Hoege et al., 2002), 
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as has been shown in the model eukaryotic organism Saccharomyces cerevisiae. 
Alternatively, Ubc13 physically interacts with Uev1A to promote NF-κB activation 
(Deng et al., 2000) by polyubiquitination of NF-κB essential modulator (NEMO) via 
Lys63-linked chains (Andersen et al., 2005).  The entire pathway is explained and 
discussed in Section 1.3. 
 
1.2  Mms2 and Uev1A sequence, structure and functional similarities 
 Both Mms2 and Uev1A interact with Ubc13 for Lys63-linked polyubiquitination 
of target proteins.  Additionally, Mms2 and Uev1A share 90% identity in sequence 
(Figure 1-1) and, although they both facilitate Lys63-linked polyubiquitin chain assembly, 
they function in distinct cellular processes as mentioned in section 1.1.  Crystal structures 
have revealed that the Mms2 monomer undergoes a localized conformational change 
upon interaction with Ubc13 (Moraes et al., 2001).  The structure of the human Mms2–
Ubc13 complex provides the foundation for understanding the mechanism of Lys63 
polyubiquitin chain assembly.  A T-shaped heterodimer is formed that allows Mms2 to 
orient an acceptor Ub through non-covalent contacts such that its Lys63 residue is 
presented to the donor Ub at the Ubc13 active site.  An isopeptide bond can then be 
formed between the two molecules and Lys63 di-Ub is free to exit through a channel 
leading from the Ubc13 active site toward a Ubl-binding site (McKenna et al., 2003; 
McKenna et al., 2001).  Mms2 is necessary for this process and, based on Ubc13-Mms2 
crystal structures, Mms2-Phe13 is responsible for the interaction between these two 
proteins (Pastushok et al., 2005). It is understood that the Uev1A-Ubc13 heterodimer 
possesses the same binding properties in order to assemble Lys63-linked polyubiquitin 
chains.  Figure 1-2 depicts a Uev1A-Ubc13 T-shaped heterodimer, donor and acceptor 
ubiquitins for the assembly of Lys63-linked Ub chains. Within the 90% sequence identity  
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Figure 1-1.  Amino acid sequence comparison of human Ubc variants Mms2, Uev1A 
Uev1A∆1-30, Uev1B and mouse Uev1A.   Numbering begins at a.a. 31 of human 
Uev1A to illustrate the differing sequences of human Mms2, human Uev1B and mouse 
Uev1A N-terminal to Gly 31.  Mms2, Uev1A and Uev1B do not share sequence 
similarity in their N-terminal a.a.  Uev1A and Uev1B share identical core sequences 
which differ from Mms2.   
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Figure 1-2.  Molecular surface of Uev1A-Ubc13 heterodimer.  Surface of the Uev1A-
Ubc13 heterodimer.  Uev1A is colored in blue, Ubc13 in red, acceptor Ub in green and 
donor Ub in gold (Hau et al., 2006). 
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of Uev1A and Mms2, they share the ubiquitin and Ubc13 binding sites.   Thus, the 
binding sites of Ub and Ubc13 to Uev1A are identical to Mms2.   
Given that both Uev1A and Mms2 are able to form a stable complex with Ubc13 
in vivo and in vitro, but their biological functions are distinct, the structural and sequence 
differences between Uev1A and Mms2 are presumed to be responsible for their 
functionally distinct intracellular signaling pathways (Andersen et al., 2005).  However, it 
is not known whether the N-terminal 30 a.a., the one a.a. substitution at 104, the seven 
unique a.a. in the core region or the C-terminal two a.a. are responsible for the important 
functional differences between Uev1A and Mms2.  Interestingly, Uev1A has been 
implicated in tumorigenesis due to its role in NF-κB activation, whereas Mms2 has no 
role in this process (Andersen et al., 2005). 
 
1.3  Ubc13-Mms2 heterodimer function in error-free postreplication repair 
The living cell is susceptible to spontaneous and environmental DNA damage. 
Genome instability may cause cell death, carcinogenesis, mutational genetic variability 
and ageing when such damage is incurred.  Eukaryotic DNA repair pathways are highly 
conserved from yeast to humans.  Three epistasis groups have been identified with 
respect to eukaryotic DNA repair mutants (Prakash et al., 1993).  The RAD3 group 
mediates nucleotide excision repair, the RAD52 group mediates double-strand break 
repair and the RAD6 group acts on the stalled replication machinery that has encountered 
a damaged template (Prakash et al., 1993).  The RAD6 mode of repair seems to be 
employed through at least two different RAD6-dependent mechanisms (Xiao et al., 1999).   
Firstly, error-prone DNA repair uses particular translesion polymerases that place correct 
or incorrect nucleotides across a damaged site.  Secondly, the other RAD6-dependent 
mode is error-free because it inserts the correct nucleotide by using the information found 
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on the undamaged sister duplex at the replication fork.  Yeast Mms2 is required for this 
error-free mode of post replication repair to prevent spontaneous and damage-induced 
mutagenesis and genome instability (Broomfield et al., 1998).  The yeast Ubc13–Mms2 
complex targets PCNA for Lys63 Ub chain assembly (Hoege et al., 2002).  However, 
proteins important for DNA repair that are targeted by Mms2-Ubc13 have remained 
unidentified.  The Mms2-Ubc13 complex is therefore regarded as a defender against 
genome instability and carcinogenesis, whereas the Uev1A-Ubc13 complex is regarded 
as an activator of an anti-apoptotic and carcinogenic pathway.   
 
1.4  Ubc13-Uev1A heterodimer function in NF-κB activation 
There are five proteins which belong to the NF-κB family (Gilmore, 2006).  
These are called NF-κB1 (p50/p105), NF-κB2 (p52/p100), RelA, RelB and c-Rel.  All 
proteins of the NF-κB family share a Rel homology domain in their N-terminal halves.  
NF-κB1 and NF-κB2 proteins are synthesized as large precursors, p105 and p100, which 
undergo processing to generate the mature NF-κB subunits, p50 and p52, respectively.   
The processing of p105 and p100 is mediated by the Ub/proteasome pathway and 
involves selective degradation of their C-terminal region.  While the generation of p52 
from p100 is a tightly regulated process, p50 is produced from constitutive processing of 
p105 (Karin and Ben-Neriah, 2000; Senftleben et al., 2001).  From this point in this thesis, 
when NF-κB is written it will refer to p50 and p65. 
Activation of the NF-κB signal transduction pathway is normally initiated by 
extracellular signals such as tumor necrosis factor α (TNFα), interleukins, ultraviolet 
irradiation and bacterial or viral infections.  As is illustrated in Figure 1-3, receptor 
activation signals a cascade of events that eventually unite onto inhibitor of κB kinase 
(IKK).  IKK consists of two kinase subunits (IKKα and IKKβ) and a regulatory subunit 
[IKKγ or   NF- kB   Essential Modulator (NEMO)].   Essentially,   this   frees   the NF-κB    
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Figure 1-3.  NF-κB activation following ubiquitination of NEMO/IKKγ by Uev1A-
Ubc13.  TNFα binding to its receptor, tumor necrosis factor receptor (TNFR), initiates 
the interaction between tumor necrosis factor receptor associated death domain (TRADD), 
receptor interacting protein 1(RIP1) and tumor necrosis factor associated-factor 2/6 
(TRAF2/6).  Ubc13 and Uev1A act as an Ub-conjugating enzyme heterodimer to 
ubiquintate NEMO and RIP1 through Lys63-linked Ub chains.  This is required for IκBα 
phosphorylation and, subsequently, NF-κB activation.  NF-κB can then freely travel into 
the nucleus where it acts as a transcription factor for activating cell survival genes.  
Figure adapted from Syed et al., 2006. 
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transcriptional activator to translocate into the nucleus and activate an array of target 
genes (Hayden and Ghosh, 2004), while IκBα is targeted to the 26S proteosome through 
Lys48-linked polyubiquitination. 
 The role of Lys63 polyubiquitin modifications in the NF-κB cascade has recently 
received considerable attention.  NEMO/IKKγ is a cellular target of Lys63 
polyubiquitination, which requires the Ubc13-Uev1 complex with TRAF2 or TRAF6 as a 
Ubl (Deng et al., 2000).  The Ubc13-Uev1 heterodimer is also involved in Lys63 
polyubiquitination of RIP1 (Wertz et al., 2004), which is required for NF-κB activation in 
response to TNFα (Lamothe et al., 2007).  Ubc13-Uev1A dependent Lys63-linked 
polyubiquitination of NEMO/IKKγ activates IKK to phosphorylate IκBα, an inhibitory 
protein that retains NF-κB subunits in the cytoplasm.  NF-κB is a transcription factor that 
regulates immune responses and inflammation through the expression of many genes, 
including those coding for cytokines, chemokines and adhesion molecules (Perkins, 
2006).  Once NF-κB has been freed to translocate to the nucleus, following 
phosphorylation of Iκ-Bα, it acts as a transcription factor for over 150 genes.  These 
genes are in categories of chemokines/cytokines, immunoreceptors, antigen presentation, 
cell adhesion molecules, acute phase proteins, stress response genes, cell surface 
receptors, regulators of apoptosis, growth factors/ ligands, early response genes and 
transcription factors/ regulators.  NF-κB can be considered a proto-oncogene as its 
activation has been implicated in many cancers and other diseases  
 
1.5  NF-κB or Uev1A overexpression causes uncontrollable cellular proliferation 
Analysis of NF-κB-deficient mice and cells led to the discovery of a novel 
function for this versatile transcription factor in the inhibition of apoptosis as seen in 
Figure 1-4. One study found that  mice deficient in NF-κB died at  embryonic  day 15 due  
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Figure 1-4.  NF-κB is a transcription factor responsible for regulating anti-apoptosis.  
Downstream genes transcriptionally activated by NF-κB directly inhibit caspase and the 
mitochondrial cytochrome C apoptotic pathways (Lin and Karin, 2003). 
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to massive apoptosis of the hepatocytes in the liver (Beg et al., 1995).  NF-κB-deficient 
mouse fibroblasts were also found to exhibit enhanced sensitivity to pro-apoptotic stimuli 
such as TNFα.  TNFα is a poor inducer of apoptosis unless RNA or protein levels are low.  
However, when there was a deficiency in NF-κB and these cells were primed with TNFα, 
apoptosis was evident.  Activation of NF-κB ablates TNFα’s pro-apoptotic activity (Beg 
and Baltimore, 1996; Van Antwerp et al., 1996).  This is because certain NF-κB target 
genes code for inhibitors of caspase activation and apoptosis (Kucharczak et al., 2003).  
The suppression of apoptosis by NF-κB is an important component of TNFα biology.  In 
addition to suppression of TNFα-induced apoptosis, NF-κB inhibits apoptosis induced by 
a variety of DNA-damaging chemotherapeutic drugs and ionizing radiation in epithelial 
cells (Papa et al., 2004; Sakon et al., 2003). 
Cellular mutational events leading to overexpression of NF-κB amplifies anti-
apoptotic signaling.  Recent discoveries show that Uev1A overexpression may also play a 
role in tumorigenesis.  Uev1A has been recognized to be upregulated in immortal cells.  
Specifically, a five- to six-fold elevation in UEV1A expression was observed in SV40-
transformed human embryonic kidney cells immediately following proliferative crisis, 
suggesting a potential role for these genes in immortalization (Ma et al., 1998). UEV1A 
expression has been shown to be increased in a variety of immortal tumor-derived cell 
lines compared to their normal tissue (Broomfield et al., 1998; Ma et al., 1998). Simply 
stated,   Uev1A activates NF-κB, which   assists in anti-apoptosis signaling.   If any of the  
Activating proteins in this signaling pathway were mutationally overexpressed, 
oncogenesis could result.  Constitutive high-level expression of UEV1A alone in cultured 
human cells was found to be sufficient to cause a significant increase in NF-κB activity as 
well as the expression of its target anti-apoptotic protein, Bcl-2 (B-cell leukemia/ 
lymphoma 2) (Syed et al., 2006).  Overexpression of UEV1A also allowed prolonged cell 
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survival under serum-deprived conditions and protected cells against apoptosis induced 
by diverse stressing agents.  All effects seen with overexpression of UEV1A were 
reversible upon suppression of expression by RNA interference (Syed et al., 2006).  
Hence, Uev1A is a critical regulatory component in the NF-κB signaling pathway and is a 
potential proto-oncogene.  As some tumor cells have been shown to exhibit constitutive 
Uev1A activity (Broomfield et al., 1998), targeting Uev1A may be critical for successful 
cancer therapy. 
 
1.6  Rationale for targeting Uev1A: the unique challenge of this research project 
Many observations, thus, collectively support UEV1 as a candidate proto-
oncogene.  Therefore, obtaining a reagent capable of recognizing (and hopefully 
neutralizing Uev1A?), but not Mms2 is of significant interest.  This is a challenging task 
given that only a few epitopes are expected to exist that could be employed to distinguish 
the two proteins.  Uev1A and Mms2 differ at a.a. 82 and 92, however, these a.a. are not 
expected to be important for function as they are located within the interior of the folded 
protein structure.  The four unique sequences of Uev1A to be targeted are located in the 
30 a.a. N-terminal sequence, a.a. 104, the 14 a.a. core region around a.a. 116-129 (7/14 
variable) and the four a.a. C-terminal sequence (2/4 variable) as can be observed in the 
a.a. sequence alignment in Figure 1-1.  Recognition of these unique Uev1A sequences 
could conceivably target Uev1A, but not Mms2 in vitro and in vivo.  This could 
ultimately allow additional experimental characterization of the functional differences 
between Mms2 and Uev1A as well as facilitate recognition of Uev1A in human tumor 
tissues. 
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CHAPTER TWO 
HYBRIDOMA TECHNOLOGY 
 
2.1  The immune response to a foreign antigen 
 The immune system harbors many lines of defense against invading foreign 
antigens.  The first line of defense against invaders consists of physical barriers such as 
skin and mucosal membranes of the digestive, respiratory and reproductive tracts.  The 
innate immune system acts as the first line of defense once an invader has broken through 
the physical barriers of the organism.  The innate immune system includes neutrophils, 
macrophages, natural killer cells and the complement system that act together to respond 
quickly and strongly to invasion.  Vertebrates have a third level of defense, of most 
importance to this particular research, which is the adaptive immune system. 
 
2.2  B cell function in the immune response 
 The adaptive immune system uses a complex system of signaling between the B 
cell lymphocyte, the T cell lymphocyte and either an array of specialized cells or the 
complement system to dispose of foreign antigens.  B cells have antibodies on their 
surfaces which specifically bind to a foreign antigen (Ambrus and Fauci, 1985; Ollila and 
Vihinen, 2005).  This antigen-antibody complex is taken up by the B cell and chewed up 
by proteolysis into smaller peptides (Krieger et al., 1985).  The B cell displays these 
antigenic peptides on its surface major histocompatibility complex (MHC) class II 
molecules. This combination of MHC and antigen attracts a matching helper T cell, 
which releases lymphokines and activates the B cell (Reinherz et al., 1980). The activated 
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B cell then begins to divide and progeny cells secrete millions of copies of the antibody. 
These antigen-specific antibodies circulate in blood plasma and lymph and bind to any 
additional identical antigens present (Ollila and Vihinen, 2005).  Subsequently, this 
opsonizes the antigen for destruction by complement activation or for uptake and 
destruction by neutrophils, macrophages and natural killer cells.   
 
2.3  Antibody structure, classes and isotypes in mice 
 Antibodies are usually shown as Y shaped structures with four subunits.  As is 
shown in Figure 2-1, antibody molecules have two longer subunits called heavy chains 
and two shorter subunits called light chains (Capra et al., 1975).  Two types of light 
chains exsist, κ and λ, of which only one kind will exist in any one antibody molecule 
(Riesen, 1980).  The heavy chains are linked to each other and to the light chains by 
disulfide bridges.  Two important antibody regions were originally determined upon 
digestion with the enzyme papain (Porter, 1959).  The antigen-recognition region of the 
antibody is called Fab for ‘fragment antigen binding’.  This region contains the N-
terminal sequences of both the heavy and light chains.  The C-terminal sequence of the 
antibody molecule is called the Fc portion for ‘fragment crystallisable’ as it was orginally 
found to be crystallised at 4ºC.  The Fc portion of the antibody molecule can be imbeded 
into the cellular surface of the B cell to target antigen binding thereby causing cell 
proliferation and excretion of identical antibody molecules from these cells (Natvig and 
Kunkel, 1973). Recombination of the constant region confers whether the antibody will 
be secreted or membrane bound.  IgM and IgD antibodies can be found imbedded in the 
B cell membrane.  Additionally, the Fc portion of secreted antibodies is recognized by 
other immune system cells in order to remove the antigen-antibody complex from the 
individual’s  body.  Five  classes of antibodies exist which are named IgG, IgA, IgM, IgD,  
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Figure 2-1.  Basic antibody structure.  Two identical heavy chains and two identical 
light chains are connected by disulfide bridges to form the antibody molecule. 
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and IgE as are illustrated in Figure 2-2 (Natvig and Kunkel, 1973).  IgG is the most 
abundant   antibody in serum.    It is a monomeric antibody molecule consisting of two 
heavy and two light chains.  In mice, four isotypes exist within the IgG class which are 
named IgG1, IgG2a, IgG2b and IgG3 (Mestas and Hughes, 2004).  Each of these    
istotypes has a distinct function as determined by the Fc portion of the molecule 
(Spiegelberg, 1974).  IgG1 and IgG3 are isotypes which can support antibody-dependent 
cellular toxicity and complement-dependent cytotoxicity.  When an antibody is bound to 
a cell surface, the Fc region of the antibody and the Fcγ receptors on the immune effector 
cells such as neutrophils, macrophages and natural killer cells interact to cause cell death 
(Carter, 2001).  The specificity for antigen is not affected by the class or isotype of the 
antibody.  Any class and isotype of antibody could be specifically constructed for an 
invading antigen.  IgA is a monomeric antibody for which only one isotype exists in mice, 
versus two in humans (IgA1 and IgA2).  IgA is secreted in mucosal surfaces.  IgM 
antibodies are the first to be produced after the initial contact with antigen.  These 
molecules are pentameric, and therefore contain 10 heavy chains and 10 light chains.  
IgD has a monomeric antibody structure which functions as an antigen receptor for B cell 
induction.  IgE is also a monomeric antibody structure and is involved in the allergy and 
asthma responses. 
Before a B cell is activated by its cognate antigen, it does not secrete antibodies.  
When the B cell binds its cognate antigen with its surface IgD or IgM B cell receptor 
antibodies, and a co-stimulation signal is provided by a helper T cell the B cell will 
become activated to continue producing antibody (Reinherz et al., 1980).  Once activated, 
a B cell will produce the default IgM antibody class unless the cell takes the opportunity 
to switch the (Fc) constant region class to IgG, IgA, or IgE.  This class switching 
determines how the antibody will  function  as  indicated  in Table 2-1. 
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Figure 2-2.  The five antibody classes 
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Table 2-1. Antibody class and functional properties defined by the Fc region 
Antibody Class Functional Properties 
IgM Fixes complement  
Opsonizes target antigens 
First antibody produced 
IgA Resistant to stomach acid 
Protects mucosal surfaces 
Secreted in milk 
IgG Fixes complement  
Opsonizes target antigens 
Assists NK cells to kill 
Crosses the placenta 
IgE Defends against parasites 
Causes anaphylactic shock 
Causes allergies 
IgD Antigen receptor for B cell induction 
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  Antibody diversity is one of nature’s masterpeices.  The number of antigens an 
individual may encounter throughout their lifetime is unimaginable.  Each antigen may 
be ‘seen’ differently by each genetic individual; the antigenic epitopes to which 
antibodies are made to be specific can differ greatly from individual to individual.  An 
epitope is the specific antigenic site which the antibody will bind. Techniques such as 
limited proteolysis, epitope footprinting, epitope excision, epitope extraction and mass 
spectrophotometry are able to determine the Fab binding space (footprint) relative to the 
antigenic epitope (Hager-Braun and Tomer, 2005). Generally, epitopes can be 8-22 a.a. 
depending on the nature of the antigen and can bind to linear or folded conformations of 
a.a.  With the knowledge that there are 20 a.a., there would therefore be a total of 20 
billion combinations for an epitope of only 8 a.a. (Dreyer and Bennett, 1965).   So, how 
do B cells have a diversity of this magnitude available for the creation of antibody 
molecules? 
 B cells undergo clonal selection and modular design to create such diversity.  
Clonal selection refers to the ability of one B cell to only make antibodies of one 
antigenic epitope specificity called its ‘cognate antigen’.  Modular design refers to the 
ability of the adaptive immune system to make a myriad of antibodies from different B 
cells when needed.  Several genetic mechanisms appear to contribute to the generation of 
an indiviual’s total repertoire of antibody specificites.  B cells contain DNA which is 
specifically processed to create antibodies.  This provides the basis for such enormous 
diveristy with respect to antigen specificity (Tonegawa et al., 1977).  Firstly, both heavy 
and light chain genes utilize multiple alternative gene segments to assemble a complete 
variable region.  Light and heavy chain assembly is a proccess which is generally 
explained as variable (V), joining (J), constant (C) recombination and V, diversity (D), J, 
C recombination, respectively (Schatz, 2004). 
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Antigenic challenge leads to rapid production of low affinity antibodies.  It 
involves the proliferation of B cells drawn from a repertoire already available at the time 
of immunization.  The potential repertiore is huge, but at any given time, only a fraction 
of the potential repertoire is available through a limited number of clones expressing 
specific antibodies.  The generation of antibody diversity is further processed by somatic 
mutation. This produces high affinity antibodies, starting with the genes used in the first 
stage cells (Bothwell et al., 1981).  Hypermutation of these genes is followed by antibody 
produced with increased affinity.  The rate of mutation can reach 0.01 mutations per base 
pair per cell division (Kocks and Rajewsky, 1989). 
 
2.4  Mab methodology 
 Monoclonal antibodies (Mabs) are defined as a population of antibodies with 
single antigenic epitope specificity.  In 1975, Kohler and Milstein discovered that they 
could fuse B cells from an immunized mouse spleen to B cell myeloma cells to create 
hybridoma cells with immortal characteristics capable of secreting antibody of a single 
antigenic specificity.  This began the Mab revolution.  Mabs have become exceptional 
tools for molecular biology, biochemistry and medicine.  The mechanism of fusion 
between these two cell types is understood as a plasma membrane fusion in the presence 
of polyethylene glycol.  This creates a heterokaryon that possesses two or more nuclei.  
At the first cell division, the nuclei of the two originating cells fuse and a hybrid cell 
results.  To select for growth of only the hybridoma cells, the use of myeloma cells 
incapable of producing purines and pyrimidines is used.  Myleoma cell lines were created 
that were deleted for the enzymes thymidine kinase, hypoxanthine guanine 
phosphoribosyl transferase which are subsequently unable to synthesize DNA through 
salvage pathways.  Additionally, in the presence of the folic acid antagonist aminopterin 
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(A) the main biosytheic pathway for purines and pyrimidines is blocked.    Hypoxanthine 
and thymidine are intermediates in DNA synthesis.  Hypoxanthine and thymidine are a 
purine derivative and a deoxynucleoside, respectively. The B cells from immunized mice 
provide functioning copies of the genes that encode the enzymes thymidine kinase and 
hypoxanthine guanine phosphoribosyl transferase. Consequently, in a media containing 
hypoxanthine, aminopterin and thymidine (HAT) a myeloma cell can be ‘rescued’ by 
fusion with a B cells which has the ability to produce DNA (Littlefield, 1964).   
Therefore, hybridoma fusions are grown in HAT medium to select for single antigen-
specific antibody-secreting immortal hybridoma cells.  Myeloma cell lines which do not 
secrete antibodies have been developed for use in monoclonal fusions.  FO cells are 
commonly used for hybridoma fusions (de StGroth and Scheidegger, 1980).  There would 
be a maximum of ten possible unique combinations of heavy and light chains, which 
could be used to produce an antibody molecule, if the myeloma cell line used for a fusion 
had the ability to produce antibody. Therefore, FO cells have been genetically modified 
so they do not produce antibody on their own.   
Fusions should generally be done approximately four days after a final 
immunization with the antigen of choice.  The reason for this is that recently activated B 
cells will fuse preferentially and will continue to secrete antibody once fused.  Early after 
fusion, hybridoma cells are considered genetically unstable and may lose chromosomes.  
To support hybridoma cells, macrophages can be used to stabilize growth by providing 
growth factors and association properties.  Generally, after seven to ten days, 
macroscopically visible colonies are formed which originated from a single hybridoma 
cell following the fusion.  Screening of the supernatant from these hybridoma clones 
against the immunizing antigen allows selection of hybridomas which secrete a Mab able 
to bind to the antigen of interest. 
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2.5  Monoclonal versus polyclonal antibodies 
 The discovery of a method for fusion between normal antibody producing cells 
and murine myeloma cells to produce B cell hybridomas (Kohler and Milstein, 1975), 
presented an important immunological advance.  Before this discovery, polyclonal serum 
was only antibody option available for scientists.  Polyclonal antiserum is a mixture of 
antibodies produced by thousands of different B cell plasma clones.  Polyclonal 
antiserum may additionally contain antibodies specific for surplus antigens, such as 
impurities in the immunizing antigen.  However, some possible advantages of polyclonal 
serum are the low production costs, higher affinity, a spectrum of specific binding 
epitopes and a mixture of antibody classes.  Whereas, some advantages of monoclonal 
antibody technology are the indefinite supply of antibody with defined properties, the 
specificity for a single epitope, rapid binding to antigen, the large amount which can be 
produced and purified.  In order to obtain antibodies capable of differentiating Uev1A 
from Mms2, this Master’s work has employed Mab technology. 
 
2.6  Rationale for the development of Mabs specific to Uev1A 
The objective of this research was to obtain Mabs capable of recognizing Uev1A, 
but not Mms2.  These are located in the 30 a.a. N terminal sequence, a.a. 104, the 14 a.a. 
core region within a.a.116-129 (7/14 variable) and the four a.a. C-terminal sequence (2/4 
variable).  Hybridoma technology was the method of choice for this Master’s research 
project for many reasons.  Firstly, a pharmaceutically relevant molecule capable of 
distinguishing between these two proteins could be used as a putative inhibitor of Uev1A 
in cancer therapy.  Secondly, the necessary equipment, cell lines and expertise from Dr. 
Barry Ziola to perform this methodology were readily available.  Thirdly, hybridoma cell 
lines are generally able to provide Mabs of unlimited potential due to the immortal 
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phenotype of these cells; Mabs are naturally stable biological molecules.  Fourthly, a 
molecule capable of differentiating between Uev1A and Mms2 has been sought after for 
many years and it was expected that Mabs would have the most success as this 
methodology has been well established.  Finally, immunization of an individual can 
increase the number of autoantibodies as the individual ages (Yang et al., 1996).  
Autoreactive antibodies may be produced by memory B cells that survive the aging 
process and either become re-stimulated later in life or become no longer able to 
established tolerance mechanisms (Stacy et al., 2002).  Thus, it would be expected that 
Mabs could be produced to both the unique human Uev1A epitopes as compared to 
mouse Uev1A and, to the regions of these proteins that are identical. 
Many cancers have been treated with Mabs to target the translated product of a 
specific proto-oncogene.  This is discussed in Chapter Five.  If a Mab capable of 
recognizing the unique regions of Uev1A could be obtained, it would be of immense 
significance for not only molecular biology and biochemical research, but also as a 
possible cancer therapy or diagnostic tool.  This is a challenging task from which the 
outcome may instigate many novel discoveries. 
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CHAPTER THREE 
MATERIALS AND METHODS 
 
 Compositions of solutions, buffers, and media are given in Appendix A, and 
sources of DNA, plasmids, chemicals, equipment, supplies and computer programs are 
given in Appendix B 
 
3.1  Molecular biology techniques 
3.1.1  Plasmids and DNA 
3.1.1.1  UEV1A and UEV1B 
 The glutathione-S-transferase (GST)-Uev1A and GST-Uev1B proteins were made 
from PCR-amplified cDNA clones of UEV1A (Deng et al., 2000) and UEV1B (Rothofsky 
and Lin, 1997).  The amplified fragments were cloned into pGEX-6P (GE-Healthcare) to 
form N-terminal gene fusions to GST named pGEX-Uev1A and pGEX-Uev1B, 
respectively. 
 
3.1.1.2  MMS2 
 The GST-Mms2 protein was made using the open reading frame (ORF) from 
previously reported isolation of cDNA clones (Broomfield et al., 1998).  The ORF was 
PCR-amplified as a BamHI-SalI fragment and cloned into pGEX-6P to form an N-
terminal gene fusion to GST named pGEX-Mms2. 
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3.1.1.3  UEV1A derivatives 
The GST-Uev1A∆1-10 protein was constructed by cloning a polymerase chain 
reaction (PCR)-amplified UEV1A30-510 as a BamHI-SalI fragment into pGEX-6P to 
form an N-terminal gene fusion to GST.  The forward primer sequence was 
5’CCCGGAT CCCTGAAGTCACAAAGC-3’.  The reverse primer sequence was 5’-
GGCGTCGACTTAATTGCTGTAACACTGTCC-3'.  The final construct was named 
pGEX-Uev1A∆1-10. 
The GST-Uev1A∆1-30 protein was constructed by cloning a PCR-amplified 
UEV1A90-510 as a BamHI-SalI fragment into pGEX-6P to form an N-terminal gene 
fusion to GST.  The forward primer sequence was 5’-GCCGGATCCAT 
GGCCATCACCACAGGAGTAAAAG-3’.  The reverse primer sequence was 5’-
GGCGTCGACTTAATTGCTGTAACACTGTCC-3'.  The final construct was named 
pGEX-Uev1A∆1-30. 
 The GST-Uev1A∆1-30,∆110-130 protein was constructed using a megaprimer 
strategy employing two rounds of PCR (Tyagi et al., 2004). Figure 3-1 illustrates the 
PCR methodology for this construct.  Using GST-UEV1A∆1-89 as the template, the first 
round of PCR amplified nucleotides 297-510 with the forward primer annealing to 
nucleotides 297-330 and 392-426, thus deleting nucleotides 331-391.  The forward 
primer sequence was 5’-TTTAACAAAACTAGCAAAATGG-3’.  The reverse primer 
sequence was 5’-GGCGTCGACTTAATTGCTGTAACACTGTCC-3’.  The second 
round of PCR used an EcoRI digested UEV1A∆1-89 gene as one template and the 
megaprimer (product from round one).  The forward primer sequence used was 5’-
GCCGGATCCATGGCCATCACCACAGGAGTAAAAG- 3’.  The reverse primer 
sequence used was 5’-GGCGTCGACTTAATTGCTGTAACACTGTCC-3’. The 
resultant   PCR  fragment   containing   nucleotides 90-330 and 392-510 was digested as a  
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Figure 3-1. Polymerase chain reaction for core deletion mutants of Uev1A.  Using 
UEV1A∆1-89 as a DNA template, two primers were used to amplify the core-deleted 
megaprimer.  The megaprimer contained nucleotides 90-330 and 392-510, and was 
further used to amplify an EcoR1-digested fragment of UEV1A∆1-89.  Amplification of 
EcoRI-digested UEV1A∆1-89 and the megaprimer using forward and reverse primers, 
respectively, produced the final UEV1A∆1-89, ∆332-390 construct.  
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BamHI-SalI fragment and cloned into pGEX-6P to form an N-terminal gene fusion to 
GST.  The final construct was named pGEX-Uev1A∆1-30,∆110-130.  Figure 3-1 
illustrates the PCR methodology for this construct. 
 The GST-Uev1A44 protein was constructed by cloning a PCR-amplified BamHI-
SalI-digested fragment containing nucleotides 1-132 into pGEX-6P to form an N-
terminal gene fusion to GST.  The forward primer sequence used was 5’-
CCGGATCCATGCCAGGAGAGGTTCAAG-3’.  The reverse primer sequence used was 
5’-CCCCAGCTGCTCAAGAAGGTTGTC-3’.  The final construct was named pGEX-
Uev1A44. 
The GST-Uev1A ∆1-30F104S protein was made using two rounds of PCR (see 
Figure 3-1 for the approach). GST-UEV1A∆1-89 was used as the template for the first 
round of PCR in order to amplify nucleotides 294-510 coding region.  The forward 
primer sequence was 5’-ACCCAGAAGCACCCCCCTTTGTAAGATTTG-3’ which 
contained the F104S megaprimer a.a. point mutation, thus changing it to Ser as seen in 
the Mms2 sequence.  The reverse primer sequence was 5’-
GGCGTCGACTTAATTGCTGTAACACTGTCC-3’.  The second round of PCR used an 
EcoRI-digested UEV1A∆1-89 gene as one template and the megaprimer as the second. 
The forward primer sequence used was 5’-
GCCGGATCCATGGCCATCACCACAGGAGTAAAAG-3’.  The reverse primer 
sequence used was 5’-GGCGTCGACTTAATTGCTGTAACACTGTCC-3’.  The 
resultant PCR fragment was digested as a BamHI-SalI fragment and cloned into pGEX-
6P to form an N-terminal gene fusion to GST.  The final construct was named pGEX-
Uev1A ∆1-30F104S.   
The GST-Uev1A ∆1-30 +5 protein was constructed using two rounds of PCR (see 
Figure 3-1 for the approach). Using GST-UEV1A∆1-89 as the template, the first round of 
 27
PCR amplified nucleotides 333-510.  The forward primer sequence was 5’-
AATATGAATGGAATAAA TAATTCCAGTGGGATGGTGGACCCA-3’.  This primer 
sequence created point mutations inserting the Mms2 a.a. INNSS, therefore replacing the 
Uev1A a.a. VNSSN at a.a. 115-119.  The reverse primer sequence was 5’-
GGCGTCGACTTAATT GCTGTAACACTGTCC-3’.  The second round of PCR used 
an EcoRI-digested UEV1A∆1-89 gene as one template and the PCR amplified fragment 
as another template.  The forward primer sequence used was 5’-
GCCGGATCCATGGCCATCACC ACAGGAGTAAAAG-3’.  The reverse primer 
sequence used was 5’GGCGTCGACTTAATTGCTGTAACACTGTCC 3’.  The resultant 
PCR fragment containing nucleotides 90-510 with the point mutations at nucleotides 345-
357 was digested as a BamHI-SalI fragment and cloned into the pGEX-6P to form an N-
terminal gene fusion to GST. The final construct was named pGEX-Uev1A∆1-30+5.   
The GST-Uev1A ∆1-30+6 protein was constructed using two rounds of PCR (see 
Figure 3-1 for the approach).  Using GST-UEV1A∆1-89 as the template, the first round of 
PCR amplified nucleotides 360-510.  The forward primer sequence was 5’-
CTAATGGAGTGGTGGACGCCCG GAGCATACCAGTGCTAGCAAAA-3’.  This 
primer sequence forced a sequence of point mutations inserting the Mms2 a.a. ARSIPV 
replacing the Uev1A a.a. PRAISV at a.a. 125-130.  The reverse primer sequence was 5’-
GGCGTCGACTTAATTGCT GTAACACTGTCC-3’.  The second round of PCR used 
an EcoRI-digested UEV1A∆1-89 gene as one template and the PCR-amplified fragment 
as another template.  The forward primer sequence used was 5’-
GCCGGATCCATGGCCATCACCACAGGAGTAAAAG-3’. The reverse primer 
sequence used was 5’-GGCGTCGACTTAATTGCTG TAACACTGTCC-3’.  The 
resultant PCR fragment containing nucleotides 90-510 with the point mutations at 
nucleotides 375-390 was digested as a BamHI-SalI fragment and cloned into pGEX-6P to 
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form an N-terminal gene fusion to GST.  The final construct was named pGEX-
Uev1A∆1-30+6.   
 
3.1.2  Polymerase chain reaction 
 PCR was used to amplify DNA fragments for the purposes of cloning and 
deletion analysis of Uev1A.  Reactions were carried out in a PTC-100 programmable 
thermal controller was used as the thermocycler to carry out the various reactions above.  
As a program guideline, a denaturing temperature of 95ºC for one min was followed by 
an annealing temperature of 48ºC for 30 sec, and primer extension was carried out at 
72ºC for one min.  These three steps were repeated 30 times per reaction. 
 
3.1.3  pGEX-6P GST fusion vector 
 The pGEX-6P vector offers a tac promoter for chemically inducible, high level 
expression of the protein of interest.  Overexpression is inducible with isopropyl-β-D-
thiogalactopyranoside (IPTG) for tac promoter transcription of the GST-fusion gene.  
Uev1A, Uev1A∆1-10, Uev1A∆1-30, Uev1A∆1-30,∆110-130, Uev1A44 and Mms2 were 
cloned into BamHI-SalI restriction sites.  Fusion proteins were purified from bacterial 
lysates by affinity chromatography using a Gluathione Sepharose 4B prepacked 5 ml 
column.  Uev1A, Uev1A∆1-30, Mms2 were cleaved using the PreScission Protease 
enzyme which cleaves the protein of interest from GST between Gln and Gly as seen in 
Figure 3-2. 
 
3.1.4  DNA sequencing 
 DNA sequences were confirmed by automated DNA sequencing at the Plant 
Biotechnology Institute, Saskatoon, SK.  All constructs sequenced used forward and 
reverse primers to the pGEX-6P plasmid which were named pGEX5’ and pGEX3’, 
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Figure 3-2.  pGEX-6P cloning vector.  The map of the GST-fusion vector shows the 
open reading frame and main features.  Overexpression of a GST-fused protein of interest 
is inducible with IPTG for tac promoter transcription.  pGEX-6P has a PreScission 
Protease cleavage site as shown between the Gln and Gly.  All inserts were cloned into 
the BamHI- SalI restriction sites of pGEX-6P.  This plasmid contains an ampicillin 
resistance gene (GE Healthcare).  
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respectively.  pGEX5’ primer sequence is 5’-CTGGCAAGCCACGTTTG-3’ and 
pGEX3’ primer sequence is 5’-GGAGCTGCATGTGTCAG-3’.  Sequences were further 
examined for the intended deletions and point mutations by nucleotide sequence 
alignment with the wild type gene. 
 
3.1.5  DNA gel electrophoresis 
Plasmid DNA and DNA fragments were separated by agarose gel electrophoresis. 
Gels of 0.6% agarose were loaded into an electrophoresis apparatus filled with 1X TAE 
buffer and a current of <100 mA was allowed until the proper migration distance was 
attained.  Gels were stained in 0.5 µg/ml ethidium bromide for 5-10 min and the DNA 
was viewed using a UV trans-illuminator. 
 
3.2  Recombinant protein expression and purification 
3.2.1  Bacteria  
The bacterial strain used in this study for protein expression was BL21-CodonPlus 
(DE3)-RIL [F- ompT hsdS(rB- mB-) dcm+ Tetr galλ (DE3) endA Hte (argU ileY leuW 
Camr)].  This strain carries extra copies of the argU, ileY and leuW tRNA genes to help 
overcome codon bias.  For plasmid DNA propagation and isolation, Escherichia coli 
DH10B (F- mcrA (mrr-hsdRMS-mcrBC) 80lacZM15 lacX74 recA1 endA1 ara139 (ara, 
leu)7697 galU galK - rpsL (StrR) nupG) was used.  With the exception of the incubation 
temperatures used for protein expression (see below), bacterial cells were incubated at 
37°C.  Bacteria cultures were grown in Luria Broth (LB).  LB agar plates were prepared 
by the addition of water to a stock powder which was then autoclaved, cooled to 55°C, 
and poured into Petri plates.  When plasmid selection was required, media was cooled to 
55°C and supplemented with ampicillin to a final concentration of 50 µg/ml. 
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3.2.2  Bacterial transformation 
Transformation of competent bacterial cells was performed by electroporation. 
For an electroporation, 25 µl of competent DH10B cells, stored in aliquots at -70°C, were 
placed on ice to thaw.  Approximately 0.1 µg of plasmid DNA was added to the cells and 
allowed to incubate on ice for 45 sec.  This plasmid and cell mixture was transferred to a 
cold Gene Pulser Cuvette that was then loaded into a Bio-Rad E. coli Gene Pulser and 
administered a 1.80 kV electric pulse.  The electroporated cells were suspended into 400 
µl of SOC liquid media and were subsequently incubated in a 37°C incubator for 45 min.  
Half of the cell suspension was then spread evenly onto an appropriate selectable agar 
plate for an overnight incubation at 37°C.  Putative transformants were streaked onto 
selective medium prior to their experimental use.  For short-term storage, the bacterial 
cell plates were sealed and then placed at 4°C for up to one month.  For long-term storage, 
actively growing bacterial cultures were suspended in 10% dimethyl sulfoxide and then 
frozen and stored at -70°C indefinitely. 
 
3.2.3  Recombinant protein overexpression 
BL21(DE3)-RIL cells transformed with pGEX-MMS2, pGEX-UEV1A, pGEX-
Uev1A∆1-10, pGEX-Uev1A∆1-30  pGEX-Uev1A∆1-30∆110-130, pGEX-Uev1A44 , 
pGEX-Uev1A∆1-30F104S, pGEX-Uev1A∆1-30+5, pGEX-Uev1A∆1-30+6 and pGEX-
Uev1B were grown overnight at 37 °C in LB + amp media and then sub-cultured 1:50 
into 37°C LB + amp the following day.  Cells were allowed to grow to an optical density 
(OD) at 600 nm of between 0.6 and 0.8, and were then induced with 0.5 mM IPTG at 
37°C for 2 hours.  Cells were harvested by centrifugation at 10,000 rpm in an Avanti 
Beckman JA10.5 rotor and resuspended in phosphate-buffered saline (PBS). 
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3.2.4  Preparation of cell extract 
Crude cell extracts, from bacterial overexpression of our protein of interest, were 
kept at 4ºC and were passed through a French Press at 10,000 psi.  The soluble fraction 
was retained after centrifugation at 17,000 rpm in an Avanti Beckman JA17 rotor for 30 
min.  The soluble fraction was then run through a chromatography system for purification. 
 
3.2.5  Chromatography 
Soluble cell extracts were passed through a pre-packed 5 ml GSTrap column, 
which was then washed with 5 column volumes of 1X PBS.  GST-fusion proteins were 
eluted from the column with reduced glutathione elution buffer.  The purified proteins 
were then dialyzed into cleavage buffer and concentrated in Amicon Ultra centrifugal 54 
filter devices.  When needed, cleavage from GST was performed by the addition of 1 µl 
of prescission protease per 400 µg of fusion protein, followed by overnight incubation at 
4°C with gentle rocking.  Cleaved proteins were then run through the GSTrap column in 
order to remove the GST from the cleaved protein of interest. 
 
3.2.6  Protein analysis 
3.2.6.1  Protein concentration 
Protein concentrations were determined by using the BCA Protein Assay Kit as 
per the instruction manual.  Purified proteins were kept at -20°C for short-term use, or 
were frozen in 1 ml aliquots and kept at -70°C for long-term storage. 
 
3.2.6.2  SDS-PAGE  
Proteins were visualized using sodium dodecyl sulfate polyacrylamide gel 
electrophoresis (SDS-PAGE) in the Mini-Protean 3 gel apparatus.  Protein samples were 
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prepared at a 1:2 dilution into protein sample buffer.  The protein samples were placed in 
boiling water for 5 min and loaded onto the protein gel.  Gels were used at a 12% 
discontinuous (5% stacking, 12% separating) Tris-glycine polyacrylamide (37:1 
acrylamide: bisacrylamide) concentration.  This recipe can be found in the Molecular 
Cloning Laboratory Manual (Sambrook et al., 1989). Gels were stained with Coomassie 
Blue staining solution for at least 30 min, followed by incubation in de-stain solution 
until appropriate protein band could be visualized (after 30 min-1 hr).  
 
3.2.6.3  Western blotting analysis 
Following SDS-PAGE, the separating gels were equilibriated for 20 min in 
transfer buffer along with equal-sized polyvinylidene difluoride (PVDF) membranes and 
3M filter papers.  The components were assembled as described in manual for the Bio-
Rad trans-blot semi-dry transfer cell, which was used for the transfer of proteins onto the 
PVDF membranes. Transfers were performed at a constant current of 1 mA/cm2 for 2 hr.  
Membranes were then incubated in a blocking solution overnight at 4°C.  The primary 
antibody was diluted in 10 ml PBST and incubated with the membranes at room 
temperature (RT) for 1 hr with gentle rocking.  The membranes were washed 3 times for 
5 min each with PBST.  The rabbit-anti-goat IgG heavy and light chain alkaline 
phosphastase-conjugated and goat-anti-mouse IgG heavy and light chain alkaline 
phosphastase-conjugated secondary antibodies were diluted at 1:2,000 in 10 ml PBST 
and incubated with the membranes as with the primary antibody.  The membranes were 
then washed 3 times for 5 min each with PBS to prepare for detection.  The detection of 
alkaline phosphatase-conjugated secondary antibodies was performed by a colorimetric 
reaction using the substrates nitroblue tetrazolium chloride and 5-bromo-4-chloro-3-
 34
indolyl phosphate diluted in alkaline phosphatase buffer to 330 µg/ml and 165 µg/ml, 
respectively. 
 
3.3  Preparation for hybridoma fusions 
3.3.1  Mouse immunizations 
 Experimental procedures using BALB/c mice were approved by the University of 
Saskatchewan Committee on Ethics in Animal Experimentation.  Mice were cared for as 
prescribed by the Canadian Council on Animal Care Guidelines.  Mice were immunized 
intraperitoneally with 35 µg of purified antigen, in PBS, emulsified in Freund’s 
incomplete adjuvant, with the emulsion then dispersed into equal volume of PBS 
containing 2% Tween 80 immediately prior to injection (Herbert et al., 1965). Mice were 
boosted three times following initial immunization.  For each boost, 17.5 µg of purified 
antigen was similarly prepared as above.  The first boost was administered 33 days after 
the initial immunization.  The second boost was administered 57 days after the initial 
immunization.  The third boost was administered 100 days after the initial immunization.  
The process is depicted in Figure 3-3. 
 
3.3.2  Preparation of polyclonal serum 
 Polyclonal sera were obtained via tail bleeding of the immunized mice at 
various times following immunization with purified antigen.  Using a razor blade, a small 
cut was made along the underside of the tail vein.  Blood was placed a 4ºC for three hr.  
At that time, the blood sample was centrifuged for two min at 13,000 rpm.  Serum was 
transferred to a new eppendorf tube (E-tube) and stored at -20ºC until tested for reactivity 
to the immunizing and other antigens (see Section 3.5.1). 
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35 µg of Uev1A 
purified protein, 
Freunds incomplete 
adjuvant, and PBS with 
2%Tween 80 injected 
intraperitoneally 
Boost #1 Boost #3  Boost #2   17.5  µg 
Uev1A 
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Uev1A 
17.5  µg 
Uev1A 
   
 
 
84 hours
FUSION 
Boost tail vein prior to fusion  17.5 ug Uev1A  
 
 
Figure 3-3.  Timeline of mouse immunizations prior to hybridoma fusion.  Each 
mouse was administered the Uev1A antigen intraperitoneally, except for the final boost 
which was given via a tail vein.  Each mouse was boosted 4 times, over the period of one 
year, prior to the hybridoma fusion. 
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3.3.3  Pre-fusion boost 
 Four days prior to the hybridoma fusion, 354 days after the initial immunization, 
17.5 µg of purified antigen in PBS was injected into the tail vein.   
 
3.4  Hybridoma fusions 
3.4.1  Harvesting of macrophages 
 Four BALB/c mice were sacrificed by cervical dislocation and washed with 70% 
ethanol.  The mice were set onto their back and a small incision was made near the 
middle of the abdomen.  The skin was then separated half towards the head and half 
towards the tail.  A needle was inserted under the abdominal wall and five mls of 0.34 M 
sucrose was injected into the abdominal cavity.  The sucrose was then drawn back into 
the syringe and this process was repeated three times.  The macrophages suspended in the 
sucrose were then collected by centrifugation at 700 X g for 5-8 min.  The supernatant 
was removed and the pellet was resuspended into 100 ml of 1640 HAT media.  The 
macrophages were then plated into ten 96 well tissue culture plates to be used as feeder 
cells for the B-cell hybridomas. 
 
3.4.2  Hybridoma growth media and selection 
The main biosynthetic pathway for purines and pyrimidines is blocked by the a.a. 
antagonist aminopterin.  In the presence of aminopterin, cells which still have 
endogenous thymidine kinase and hyoxanthine quanine phosphoribosyl transferase can 
continue to synthesize DNA through DNA salvage pathways.  However, if either 
thymidine kinase or hyoxanthine quanine phosphoribosyl transferase is missing, DNA 
synthesis ceases.  Spleen cells with thymidine kinase and hyoxanthine quanine 
phosphoribosyl transferase, which would die in culture after a few days, were fused to 
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myeloma cells lacking thymidine kinase and hyoxanthine quanine phosphoribosyl 
transferase.  A single myeloma cell is subsequently rescued by a fusion with an 
immunized B cell which supplies the missing enzymes.  Only the hybrid cells will grow 
in 1640 HAT medium which contains hypoxanthine, aminopterin, and thymidine. 
 
3.4.3  Myeloma and immunized B cell fusion 
3.4.3.1  Splenectomy 
 A Uev1A-immunized mouse was sacrificed by cervical dislocation and placed 
onto its right side in a sterile tray.  The mouse was liberally washed with 70% ethanol.  
An incision was made posterior to the left side of the ribcage.  The skin was separated 
and scissors and forceps were used to remove a large skin flap over the area of the spleen.  
The facia and musculature were opened and the spleen was removed and washed in a 
dish containing 10 ml of S-O media.  The spleen was then placed into 3 ml of fresh S-O 
medium and the dish containing the spleen was transferred to a sterile biosafety cabinet.  
The spleen was poked full of holes with a 26 gauge needle and 5 ml of S-O media were 
gently forced through the spleen causing ejection of the spleen cells.  This procedure was 
repeated again.  The spleen cells are confirmed to be removed when the spleen color 
becomes relatively clear.  The cells and medium were placed into a 50 ml tube and 
centrifuged at 900 X g for seven min.  The supernatant was removed and the cell pellet 
was tapped loose in preparation for fusion with FO Myeloma cells. 
 
3.4.3.2  Preparation of Myeloma cells for fusion 
 FO cells are permanently stored in liquid nitrogen.  When needed, the FO cells 
were removed from the liquid nitrogen tank and warmed rapidly to 37ºC for two min.  
The cells were washed with 15 ml of S-10 medium and resuspended into 40 ml of S-10 
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medium. These cells were allowed to grow for approximately 5 days in preparation for 
fusion with the Uev1A-primed B cells from the splenectomy. 
 
3.4.3.3  Hybridoma fusion 
 Two hybridoma fusions were concurrently performed, one by Dr. Barry Ziola and 
one by me.  Each fusion used B cells from a separate Uev1A-immunized BALB/c mouse.  
S-O serum-free medium was used to mix 108 spleen cells and 2 X 107 myeloma cells.  
The cells were centrifuged for eight min at 400 X g and the supernatant was completely 
removed.  The pellet was broken by gently tapping the bottom of the tube.  Fusions were 
performed in a 37ºC waterbath for the remainder of the protocol.  One ml of 50% PEG, 
pre-warmed to 37ºC, was added to the pellet over a period of one min, with continual 
stirring.  Stirring of the cells was continued for two additional min.  Fourteen ml of S-O 
medium were then added slowly over fourteen min with continual stirring.  The cells 
were incubated for 5 min and subsequently centrifuged for eight min at 400 X g.  The 
supernatant was discarded and the pellet was resuspended into Rosewell Park Memorial 
Institute medium (RPMI) 1640 HAT selection media in ten 96 well tissue culture plates.  
The hybridoma cells were monitored for seven days, the medium was changed upon first 
observation of acidic pH adjustment in the media color and the cells were tested for Mab 
specificity to Uev1A after at least 25% confluency was reached. 
 
3.5  Hybridoma screening 
3.5.1  Enzyme immunoassays 
 High protein binding Immulon 4 flat-bottomed, 96 well plates were used in all 
enzyme immunoassays (EIA)s.  Antigen was plated at 0.5 µg in 100 µl of PBS per well 
and allowed to bind the plate overnight at RT.  The plate was then emptied and 
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unadsorbed antigen was removed by inverting the plate and tapping on paper towel.  The 
primary antibody was added using a dilution series or at a predetermined dilution in assay 
diluent.  Following a one-hr incubation at 37ºC, the primary antibody was dumped out 
and the plate was washed again four times with rH20 followed by tapping on paper towel 
between each wash.  The horseradish peroxidase (HRP)-conjugated secondary antibody 
was added at a predetermined dilution in 100 µl of EIA assay diluent per well.  Following 
one-hr incubation at 37ºC, the secondary antibody was dumped and the plate was washed 
four times in rH20.  A tetramethylbenzidine microwell peroxidase substrate was used to 
develop a deep blue color when reacted with HRP.  The plate was allowed to develop for 
30 min in the dark after which 1 M phosphoric acid was added to stop the reaction.  The 
acid turned the TMB substrate yellow and the reaction was read at a wavelength of 450 
nm in an EIA reader using MacReader 2.0 Software. 
 When polyclonal antiserum was assessed for antibody by EIA, a mathematical 
approach was used to determine the level (titer) of antibodies able to bind a given antigen.  
Four EIA data points were used, with the antibody dilutions involved being those 
successive two-fold dilutions that gave EIA results above and below OD450nm = 0.5.  
Reciprocals of the antiserum dilutions were converted to log10 values and a straight line 
equation was derived for these values and the associated EIA values.  The equation was 
then used to determine the antiserum dilution that would give an EIA result of exactly 0.5.  
The reciprocal of this dilution was defined as the antiserum titer. 
 
3.5.2  Ascites fluid production 
 Mabs of the desired binding specificity were subject to ascites production.  The 
hybridoma cells producing Mab specific to Uev1A were grown in tissue culture in RPMI 
1640 S-10 medium until approximately 70 percent confluency in a T75 Tissue culture 
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flask was reached. Growth of hybridomas in ascetic fluid of mice can produce from 1 to 
10 mg/ml of Mab. Mice were injected intraperitoneally with 0.3 ml of Freund’s 
incomplete adjuvant 24-48 hr prior to injection to help stimulate ascites formation.  The 
hybridoma cells were collected by centrifugation and washed twice in 50 mls of RPMI.  
Approximately 106 hybridoma cells were resuspended in 2.5 mls of RPMI and were 
injected into the peritoneum of a BALB/c mouse. Ascites fluid was produced within 
seven to fourteen days.  Ascites fluid was removed and the mice were sacrificed.  
 
3.5.3  Isotyping 
 EIAs were performed using tissue culture supernatant containing Mabs produced 
by stable hybridoma cell clones.  The 96 well EIA plate was coated with 0.75 µg per well 
of goat anti-mouse IgG + IgM heavy and light chain specific ‘trap’ antibody.  This 
antibody was allowed to adsorb to the plate overnight at RT.  Following removal of the 
unadsorbed antibody by tapping on paper towel, the tissue culture supernatant was added 
to each well at a 1:2 dilution in EIA assay diluent in a final volume of 100 µl per well.  
After 1 hr at 37ºC, the plate was emptied and washed four times in H20 and then 
secondary antibodies were added.  To discover the class and isotype of each Mabs, six 
secondary antibodies were used: anti-mouse IgGγ:HRP, anti-mouse IgG1:HRP, anti-
mouse IgG2a:HRP, anti-mouse IgG2b:HRP and anti-mouse IgM:HRP.  These secondary 
antibodies were tested in duplicate for reactivity with the Mabs.  The plate was washed, 
then developed and read as stated in section 3.5.1. 
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3.6  Competition analysis 
3.6.1  Horseradish peroxidase conjugation 
 
 HRP-conjugation was done according to a modification to the procedure of 
Nakane and Kawaoi (1974) whereby the blocking and molecular sieve chromatography 
steps were ommitted.  Ascites fluid were diluted from 2 ml to 3.5 ml with PBS and 
placed at 4°C. While stirring for approximately 2 min, 3.15 mL of RT saturated 
ammonium sulphate solution was added dropwise.  After 1 hr at 4°C, the mixture was 
centrifuged at 9,000 × g at 4°C for 10 min.  The pellet was dissolved in 3.5 ml of 4°C 
PBS and the precipitation was repeated. Recovered antibody was dissolved in 3.0 ml of 
4°C PBS and dialyzed for 2 days at 4°C against 300 volumes of 10 mM sodium 
carbonate (pH 9.5).  Fresh buffer was used each day.  Following dialysis, insoluble 
material was removed by centrifugation for 10 min at 850 × g at RT. Concentration of the 
clarified immunoglobulin solution was determined at 280 nm using an extinction 
coefficient of 13.0. 
Five mg of HRP was dissolved in 1.0 ml of freshly made 0.3 M NaHCO3.  One ml 
of 0.08 M NaIO4 was added and the contents were mixed gently for 30 min at RT.  The 
mixture turned a green-yellow color.  At this time, 1.0 ml of 0.16 M ethylene glycol was 
added and the contents were allowed to mix gently at RT for 1 hr.  The solution was 
dialyzed against three 1 L changes of 0.1 M Na2CO3. At a 1:1 mg ratio, purified Mab was 
added to aldehyde-activated HRP and allowed to mix gently at RT for 2-3 hr.  After this, 
equal mg weight of NaBH4 was added and the solution was left to mix for 3 hr.  The 
solution was then dialyzed against three 1 L changes of PBS at 4ºC.  Merthiolate was 
added to 0.2 mM and the conjugates were stored at 4°C for the duration of the 
experiments. 
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3.6.2  Epitope mapping 
3.6.2.1  Titration of HRP:Mab conjugates 
 The dilution of each conjugate giving a background-corrected OD450 nm value of 
l.0 was determined by an EIA in 96 well Immulon 4 plates.  Uev1A was allowed to bind 
the plate at a concentration of 0.5 µg in a dilution of 100 µl per well of PBS overnight at 
RT.  Removal of buffer and unadsorbed antigen from each well was performed by 
inverting the plate and tapping on paper towel.  Assay diluent (100 µl) was added into 
each well to block the plate.  Dilutions of HRP–Mab conjugates were made in assay 
diluent and 100 µl of each dilution were added to four wells.  After one hr at 37°C, the 
solution was dumped from the well and the wells were washed four times in RT rH2O, 
followed by inversion and tapping of remaining fluid on paper towel.  Each well received 
100 µl of substrate solution.  After 30 min at RT in the dark, 100 µl of 1 M phosphoric 
acid were added per well and the plates were read as described in section 3.5.1. 
 
3.6.2.2  Mab competition EIAs 
 To determine whether an unconjugated Mab was able to inhibit the binding of an 
HRP-conjugated Mab, two EIAs were performed using the same Mab dilutions.  Firstly, 
in a direct Mab binding EIA, 100 µl of each Mab dilution were added to a single well 
containing adsorbed Uev1A.  The Mab dilution giving a background-corrected OD of 1.0 
was found by linear interpolation, using the three dilutions yielding assay values closest 
to 1.0.  In the second EIA, a Mab binding competition EIA, 100 µl of each Mab dilution 
was again added to a single well containing adsorbed Uev1A.  Unlike the Mab direct 
binding EIA, however, the plates here were not dumped and washed after the initial 1 hr 
incubation at 37°C.  Instead, 100 µl of HRP-conjugated Mab was directly added to each 
well, with the dilution used being that giving a final background-corrected OD450 nm value 
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of 1.0 as determined by the titration EIA in section 3.6.2.1.  Eight wells that received 
only assay diluent during both incubations were used to determine the assay background 
value for that plate.  Similarly, for each plate, eight wells receiving assay diluent during 
the first incubation and diluted HRP-conjugated Mab during the second incubation were 
used to determine the background-corrected OD450 nm value for 100% binding of the 
HRP-conjugated Mab.  The dilution of unconjugated Mab which gave 50% inhibition of 
HRP-conjugated Mab binding was determined by interpolation using the three dilutions 
yielding inhibition values closest to 50%.  Because Mabs in ascites fluid were used in 
these competition EIAs, the ability of each Mab to hinder binding of a given HRP-
conjugated Mab was related to the Mab dilution that gave an assay background corrected 
OD450 nm value of 1.0 in the direct Mab binding EIA.  The following formulas were 
constructed to calculate the competition (Ziola et al., 1999). 
 
Reciprocal of dilution giving a direct binding EIA value of 1.0   = Competition index 
Reciprocal of dilution giving a competition EIA value of 50% 
 
 
The competition index for each Mab was then related to the competition index for the 
Mab conjugated with HRP (i.e., the homologous Mab) according the following formula: 
 
        Mab competition index      = Relative competion index 
Homologous Mab competition index 
 
 
By mathematical definition, the relative competition index for the unconjugated 
homologous Mab will be 1.0.  Any Mab with a relative competition index much larger 
than 1.0 is considered to be unable to inhibit binding of the HRP-conjugated Mab.  Any 
Mab with a relative competition index less than 1.0 is considered to have the capability, 
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based on binding topography, to compete with an HPR-conjugated Mab better than it can 
with its homologous HRP-Mab.  For example, if one Mab is binding to a three 
dimensionally more topographically accessible distinct site, it can block the binding of an 
HRP-conjugated Mab which binds to a less topographically accessible distinct site.  In 
this case, the unconjugated Mab would be capable of blocking the binding of the HRP-
conjugated Mab better than it can block a Mab identical to itself; a relative competition 
index of less than 1.0 would result. Mab 2H11 was also used in the competition 
experiments. It is a Uev1A- and Mms2-binding Mab that originated in Dr. Wei Xiao’s lab 
and was produced by Parker Andersen.  
 
3.7 Formalin-fixed paraffin-embedded tissue immunohistochemistry 
Paraffin blocks containing embedded tissue were cut to 4 micron thickness and 
then tissue sections were placed on positively charged slides.  Normal thyroid tissue was 
used as a positive control for Uev1A staining based on a screen of mRNA by Northern 
blot (data not shown).  Slides with unstained sections were stored at 4ºC if used 
immediately and at -70ºC for long term storage.  Slides were prewarmed to RT and dried 
before they were baked at 60ºC overnight prior to the immunoassay.  The slides were 
deparaffinized and rehydrated as follows: four 5 min washes in xylene, three quick 
washes in 100% ethanol, two quick washes in 95% ethanol and one 5 min wash in 70% 
ethanol.  Following tissue-rehydration, heat-induced epitope retrieval was done by 
cooking slides in a microwave oven in 1 mM ethylenediamintetraacetic acid (EDTA) 
buffer at pH 9.0.  Endogenous peroxidases were blocked in the tissue slides by incubating 
for 10 min in 3% hydrogen peroxide in methanol to reduce false-positive staining.  The 
slides were rinsed in rH2O three times for 5 min for rehydration and were then stored in 
rH2O until the immunoassay was performed.  
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 The formalin-fixed paraffin-embedded tissue slides were incubated with 200 µl of 
the primary antibody at a 1/50 dilution in immunohistochemistry antibody-dilution buffer.  
In addition, Mab LN1 antibody was also pre-absorbed by Uev1A protein by incubating 
the mixture for 12 hours prior to use with Uev1A protein at a concentration of 0.2 mg/ml.  
Both, Mab LN1 and Uev1A-preabsorbed Mab LN1 solutions were added to the 
respective slides and incubated overnight at 4ºC in a hydration chamber.  Secondary 
antibodies reactions for visualization of the bound primary Ab were performed using the 
Envision Dako Kit.  Slides were gently rinsed in PBS by placing them in a Coplin jar for 
three 5 min washes.  Excess buffer was removed and slides were placed in a humidity 
chamber one at a time and dehydrated with three-four drops of HRP labeled secondary 
anti-mouse antibody solution.  The solution was incubated at RT for 30 min.  Slides were 
then rinsed and incubated with 200 µl of diaminobenzidine chromagen substrate for 10 
min and rinsed with PBS.  After rinsing, the slides were washed three times for 5 min in 
PBS.  For color enhancement, subsequently the slides were incubated in a 2% copper 
sulphate solution for 5 min and then rinsed well with rH2O.  Slides were then dipped in 
Haematoxylin 1 fifteen times, and then washed in rH2O until slides were completely clear, 
which was used as a counterstain to visualize the nuclei of the cells.  Slides were 
immediately dehydrated for cover slipping as follows: three times in 95% enthanol, three 
times and 100% ethanol and four times in xylene.  Slides were then stored in a final 
xylene wash and mounted one at a time using appropriately sized coverslips and 2-3 
drops of cytoseal mounting solution (performed by Dr. Emina Torlakovic).   
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CHAPTER FOUR 
RESULTS 
 
4.1  Purified Uev1A, Uev1A∆1-30 and Mms2 proteins 
 The central goal of this thesis research was to obtain Mabs capable of recognizing 
and distinguishing Uev1A from Mms2.  In order to carry out the stated objective, 
purification of proteins of importance, namely, Uev1A and Mms2 was necessary.  
Genetic cloning of MMS2 and UEV1A full length, deletion and mutational constructs into 
the pGEX-6P GST-fusion vector facilitated overexpression of the respective proteins for 
protein purification.  Each inserted gene was constructed by PCR using the restriction 
sites BamH1 and Sal1, and ligated into a BamH1-Sal1-digested pGEX-6P vector as 
illustrated in Figure 3-2.  Protein purification was performed using glutathione sepharose 
column chromatography and the resultant Mms2, Uev1A and Uev1A∆1-30 proteins were 
obtained at high purity as shown in Figure 4-1.  The GST-fusion protein was cleaved 
from these overexpressed proteins in the purification process.    
 
4.2  Mouse immunizations and polyclonal antibody response to Uev1A and Mms2  
Full-length Uev1A was used for immunization of BALB/c female mice over the 
course of one year.  The mice were immunized a total of five times as can be seen in the 
timeline provided in Figure 3-3.  Polyclonal serum was obtained and directly tested in an 
EIA against Uev1A and Mms2 antigens. At an OD450nm of 0.5, titers of 275,000, versus 
95,000,   a 3-fold   difference, was  found  for  antibody  binding   to   Uev1A  and Mms2,  
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Figure 4-1. SDS-polyacrylamide gel of purified proteins Mms2, Uev1A and 
Uev1A∆1-30.   Mms2, Uev1A and Uev1A∆1-30 were purified using GST-column 
chromatography to final GST-cleaved concentrations of 0.15 mg/ml, 0.2 mg/ml and 
0.185 mg/ml, respectively.  Ten microliters of each purified protein sample were 
analyzed.   The gel was stained with Coomassie blue.  
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respectively.    These results are presented in Figure 4-2.  Additionally, response to any 
residual cleaved GST-impurities in the immunizing antigen proved to be negligible in 
line with the purity of the Uev1A antigen observed in Figure 4-1.  The differential 
response observed provided confidence in the likelihood of producing Mabs specific to 
Uev1A.  Consequently, Dr. Barry Ziola and I each performed a hybridoma fusion with 
one of the Uev1A-immunized BALB/c mice.  In each fusion, the mouse spleen was 
removed and B cells were fused with FO Myeloma cells. 
 
4.3  Mab binding to Mms2, Uev1A and Uev1A∆1-30 
Analysis of Mabs secreted in the supernatant of hybridoma cell growth medium 
was performed using EIAs.  Nine hundred and sixty hybridomas were tested for a binding 
response to Uev1A and Mms2.  Of these nine hundred and sixty hybridomas, twelve 
secreted Mabs capable of interacting only with Uev1A, while one secreted a Mab capable 
of interacting with both Uev1A and Mms2.  Of the twelve Uev1A-specific Mabs, six 
interacted only with Uev1A and the other six interacted with both Uev1A and Uev1A∆1-
30.   The immunoglobulin class for each of the original thirteen hybridoma clones is 
outlined in Table 4-1 along with the successfully recloned renamed hybridomas. 
Following selection using specific criteria, five Mabs were obtained and successfully 
recloned.  IgM and mixed IgM/IgG Mabs were discarded from the Uev1A screen due to 
the IgM pentameric bulky structure.  Six additional Mabs lost reactivity over the 
screening period.  Four of the five remaining Mabs are specific to Uev1A and not Mms2, 
and the other Mab reacts with both.  As shown in Tables 4-1 and 4-2, the five remaining 
Mabs have been renamed LN1, LN2, LN2A, LN2B and LN3.  The original names of 
each hybridoma cell line are shown in Table 4-1 to provide a published link to the 
original raw data obtained.        
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Anti-Uev1A polyclonal serum reactivity to Uev1A, Mms2, and GST
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Figure 4-2. Binding of anti-Uev1A polyclonal antibodies to GST, Mms2 and Uev1A.  
The 3-fold higher reactivity to Uev1A demonstrates the putative antibody reactivity 
specific to the four unique regions of Uev1A.   
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Table 4-1.  Antibody classes of hybridoma clones.   
Original Name New Name Class 
Z1-D8 -* IgG 
N3-E2 - IgG and IgM 
N1-E5 - IgM 
N1-H2-A6 LN2 IgG 
Z4-F12 - IgG 
Z1-F3 - IgG 
Z1-F1 - IgG 
Z4-A8 - IgG 
Z4-D4-B3 LN2B IgG 
Z4-G7 - IgG and IgM 
Z1-B3-A11 LN1 IgG 
N4-B4-B3 LN2A IgG 
Z5-D2-F12 LN3 IgG 
*Dashed line represents the absence of a new name due to being unable to establish a 
stable recloned hybridoma cell line. 
 
 
Table 4-2.  Phenotypic interaction profiles of Mabs secreted by hybridoma cell lines.   
Renamed 
Hybridoma 
Cell Lines 
Uev1A          Uev1A∆1-30         Mms2 Mab Isotype 
LN1 +                        -                            - IgG1 
LN2 +                        +                           - IgG2b 
LN2A +                        +                           - IgG1 
LN2B +                        +                           - IgG1 
LN3 +                        +                           + IgG2b 
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Using Uev1A, Uev1A∆1-30 and Mms2 purified proteins, analysis was carried out 
to characterize binding to the N-terminal 30 a.a. of Uev1A as well as to observe a 
differential binding of Uev1A and Mms2.  Figure 4-3, Figure 4-4 and Table 4-2 show 
that Mab LN1 binds to Uev1A, but not Mms2 or Uev1A∆1-30, providing a possible 
Uev1A N-terminal specific antibody.  Mabs LN2, LN2A and LN2B have been named 
because they all bind to Uev1A and Uev1A∆1-30, but not Mms2, providing three 
possible core-specific Mabs.  These three Mabs share the same antigen binding profile, 
but originated from independent hybridomas.  Mab LN3 binds to all three antigens and 
therefore does not distinguish between Uev1A and Mms2. 
 
4.4  Mab binding to Uev1A-deletions  
In order to characterize the antigenic epitopes of Mabs LN1, LN2, LN2A, LN2B 
and LN3, deletion and mutational constructs of Uev1A were made by using PCR, site-
directed mutagenesis and molecular cloning techniques.  Using these constructs, the exact 
binding locations were determined due to a loss of binding when epitopes were deleted or 
mutated.  These constructs included Uev1A44, Uev1A∆1-10 and Uev1A∆1-30∆110-130.  
The a.a. sequence alignment and comparative sequence illustrations of these proteins are 
shown in Figure 4-5. These protein constructs were overexpressed in E.coli and used for 
Western blotting directly without further chromatography purification.  As seen in Figure 
4-6, Mab LN1 reacts with Uev1A, Uev1A∆1-10, Uev1A44 but not Uev1A∆1-30, 
Uev1A∆1-30∆110-130, Uev1B and Mms2, making it specific for a.a. 10-30 of Uev1A. 
Mabs LN2, LN2A and LN2B Mabs react with Uev1A, Uev1A∆1-10, Uev1A∆1-30 and 
Uev1B, but not Uev1A44, Uev1A∆1-30∆110-130 and Mms2, making them specific for 
the core a.a. 110-130 of Uev1A.  Lastly, Mab LN3 reacts with all seven constructs, 
making it specific for a.a. 30-44 of Uev1A and Mms2. 
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 Enzyme Immunoassay :  Absorbance at OD450nm of monoclonal antibodies LN1, LN2 and LN3 
showing binding specificity to hUev1A, hUev1A30, hMms2
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Figure 4-3.  EIA at OD450  nm for Mabs against Uev1A, Uev1A∆1-30 and Mms2.  
Mabs LN1, LN2, LN2A, LN2B and LN3 binding specificity to Uev1A, Uev1A∆30 and 
Mms2 as determined by the absorbance at OD450  nm.  Mabs in the form of ascites fluid 
were used. 
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Figure 4-4.  Western blot analysis of Mabs LN1, LN2, LN2A, LN2B and LN3.  
Proteins Uev1A, Uev1A∆1-30 and Mms2 were transferred to a PVDF membrane and 
Mab ascites fluid, at a dilution of 1/2,000, was used as the primary antibody. 
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Figure 4-5.  A. Amino acid sequence comparison of human U
Mms2, Uev1A and Uev1A-deletion constructs. Numbering is b
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 55Amino AcidMms2 
bc variants Uev1B, 
ased on Uev1A a.a. 
of Uev1A-deletion 
 Mms2 and Uev1B, 
 
 
Mab 
LN1 
 
 
 
Mab 
LN2 
Mab 
LN3 
Mab 
LN2A 
Mab 
LN2B 
Anti-GST 
 
 MW 20K   
 50 
  
37     
  
  
20  
  1   2   3   4   5   6   7  
 
1    2   3   4   5    6   7   1   2   3   4   5   6   7  1   2   3   4   5   6   7   1   2    3    4   5  6 7  1   2   3   4   5    6   7 
 
 
 
 
 
 
 
Legend 
 
 
Uev1A∆1-10 
Uev1A∆1-30 
Uev1A∆1-30, ∆110-130 
10 30 44 110 130 Amino Acid  
 
 
 
 
 
 
 
 
1 
2 
3 
4 
5 
6 
7 
N Uev1A 
 
 
Uev1A44 
Uev1B 
Mms2 
 
 
 
 
Figure 4-6. Western blotting analysis showing specificity of Mabs to Uev1A.  Binding 
specificity of Mabs, was determined using five Uev1A-deletion constructs, Mms2 and 
Uev1B in Western blotting. Green and orange colors designate amino acids in Mms2 and 
Uev1B, respectively, which are not the same as Uev1A. 
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Mab LN1 only shows a binding response to Uev1A, Uev1A∆1-10 and Uev1A44 
in Western blot analysis.  This result provides evidence that when a.a. 10-30 are missing 
Mab LN1 will not bind the protein and when they are present binding is observed.  Mabs 
LN2, LN2A and LN2B show similar binding phenotypes to one another.  All three Mabs 
bind to Uev1A, Uev1A∆1-10, Uev1A∆1-30 and Uev1B.  This provides evidence of 
binding to the Uev1A unique core region as the other constructs are missing a.a. 110-130.  
Mab LN3 interacts with all constructs used in Figure 4-6, even Uev1A44. Its binding 
specificity can be deduced as a result of Mab LN3’s ability to bind to Uev1A, Mms2 and 
also Uev1A44.  As Mab LN3 does bind to Uev1A∆1-30, it must be interacting within a.a. 
30-44 of Uev1A. 
 
4.5  Competition analysis and epitope mapping of Mabs 
 In addition to characterizing specific sequence targets of each Mab, the question 
arose of how many epitopes Mabs LN2, LN2A and LN2B bound to in the unique core 
region of Uev1A.  In order to answer this question, each Mab’s ability to compete with 
every other Mab was tested.  In order to perform competition analysis, Mabs LN1, LN2, 
LN2A, LN2B and LN3 were each conjugated to HRP.  Essentially, epitope mapping 
investigated the ability of each Mab to compete with the HRP-conjugated homologous 
Mab and all other HRP-Mabs to bind Uev1A in EIAs.  For example, Mab LN1-HRP was 
allowed to bind Uev1A following binding of Mab LN1, LN2, LN2A, LN2B or LN3 
binding to Uev1A.  Enzyme substrate was allowed to develop and only if Mab LN1-HRP 
was able to bind would color development be observed.  The relative competition index 
is calculated as explained in Section 3.6.2.2.  Firstly, the reciprocal dilution from the 
direct binding assay at OD450 nm = 1.0 is defined as 100% binding and this is compared to 
the ability of the Mab-HRP to compete at 50%.  This was called the competition index.  
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This value was then divided by the homologous Mab competition index.  Therefore, these 
calculations define the ability of one Mab to compete with another given Mab-HRP by 
directly comparing it to the ability of that particular Mab to compete with its own (i.e,  
the homologous) Mab-HRP. Using this theory and methodology it has been concluded, as 
seen in Table 4-3, that Mab LN1 competes with Mab LN3 and Mab LN2 competes with 
Mab LN2B.  Additionally, Mab LN1 competes Mab LN3 better than Mab LN3 can 
compete Mab LN1.  
 Illustrations of Uev1A structure and Mab binding competition are shown in 
Figures 4-7 and 4-8.  Fundamentally, because Mabs LN1 and LN3 are spatially adjacent, 
it is possible that they could inhibit binding of each other to variable extents.  Mabs LN2 
and LN2B are proposed to both bind the same sequence within the core 110-130 a.a. of 
Uev1A and, Mab LN2A is also defined to bind to that region.  However, binding of Mab 
LN2A-HRP is not inhibited by Mabs LN2 or LN2B nor are Mabs LN2-HRP or LN2B-
HRP inhibited by binding of  Mab LN2A.  Mab 2H11 is a Uev1A- and Mms2-binding 
Mab produced by Parker Andersen which does not appear to inhibit the binding of any 
other Mab, including Mab LN3, which also binds to both Uev1A and Mms2. 
 
4.6 Epitopes in the core region of Uev1A 
 Following extensive study of the core structure of Uev1A, using NMR solution 
structure data, three putative antibody epitopes have been revealed.  As can be observed 
in Figure 4-9, the unique Phe104, the unique sequence VNSSN at a.a. 115-119 and the 
unique sequence PRAISV at a.a. 125-130 may form three unique core epitopes.  The 
possibility that there are three binding epitopes within the core region supports the notion 
that  sequence  differences between  Uev1A and  Mms2 may be critical to their functional  
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Table 4-3.  Relative competition index of Mabs.   
Competing Mab 
Mab:HRP Mab LN1 
 
Mab LN2 Mab LN2A Mab LN2B Mab LN3 Mab 2H11 
Mab LN1-
HRP 
 
1 >50 >50 >50 6.5 >50 
Mab LN2-
HRP 
 
>50 1 >50 0.5 >50 >50 
Mab LN2A-
HRP 
 
>50 >50 1 >50 >50 >50 
Mab LN2B-
HRP 
 
>50 2.1 >50 1 >50 >50 
Mab LN3-
HRP 
 
0.9 >50 >50 >50 1 >50 
Bolded numbers are to emphasize the competition between Mabs LN1/LN3, and Mabs 
LN2/LN2B for binding to Uev1A.  A value of >50 indicates the two Mabs do not inhibit 
each other’s binding. 
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Figure 4-7.  Putative binding competition for Mabs LN1 and LN3.  Mabs LN1 and 
LN3 inhibit one another from binding to their distinct epitopes. A. Mab LN1 binds to the 
unique 10-30 a.a region of Uev1A.  B. Mab LN3 binds to the Mms2 common 30-44 a.a 
region of Uev1A.  These sequences are spatially adjacent. 
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Figure 4-8.  Putative binding competition for Uev1A unique core specific Mabs LN2, 
LN2A and LN2B.  Mabs LN2 and LN2B inhibit one another from binding to the same 
epitope, but neither inhibits Mab LN2A.  All three Mabs bind within the a.a. 110-130, 
where seven of fourteen a.a. are variable between Uev1A and Mms2. 
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differences within cellular signaling pathways.  The three-dimensional structure in Figure 
4-9 shows how  Phe104 may be part   of an epitope   which is distinct from the VNSSN at  
a.a. 115-119 or it may be part of the same epitope due to its  adjacent location in the 
folded protein.  These three putative epitopes in the core region are found opposite to the 
Ub binding site and independent of the Ubc13 binding site.  The side chains of   Uev1A-
Ile57 and Ub-Ile44 are required for Ub binding to the acceptor site of the Uev1A-Ubc13 
complex for chain assembly in vitro.  Uev1A-Asn37 and Uev1A-Phe38 have been shown 
to be required for binding to Ubc13 (Pastushok et al., 2005).  Consequently, defining the 
three Mabs (LN2, LN2A and LN2B) to the unique core region of Uev1A and one Mab 
(LN1) to the N-terminal unique region of Uev1A could be of great potential to research, 
diagnostics and therapeutics in cancers stimulated by Uev1A/NF-κB. 
 
4.7  Uev1A core mutations: Mab reactivity to a.a. mutations in variable core 
Three mutants of UEV1A were cloned into pGEX-6P.  These UEV1A mutants 
contained a.a. substitutions changing them from the Uev1A to the Mms2 sequence within 
the variable core region.  Firstly, a Uev1A∆1-30 construct was created containing an 
Phe–to-Ser mutation at a.a. 104.  This construct was named Uev1A∆1-30F104S.  
Secondly, a Uev1A∆1-30 construct containing a five amino-acid substitution from a.a. 
115-119 of Uev1A was constructed.  The a.a. were changed from the Uev1A sequence 
VNSSN to the Mms2 sequence INNSS.  This construct was named Uev1A∆1-30+5.  
Finally, Uev1A∆1-30 construct containing six a.a. substitutions from a.a. 125-130 of 
Uev1A was constructed.  The a.a. were changed from the Uev1A sequence PRAISV to 
the Mms2 sequence ARSIPV.  This contruct was named Uev1A∆1-30+6.  These proteins 
were  all  fused to  GST when  overexpressed  in E. coli RIL cells.  Crude protein extracts  
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Figure 4-9. Three putative core epitopes in Uev1A.  Uev1A is seen here in purple.  
Blue color highlights the Uev1A unique a.a. Phe104.  Green color highlights the Uev1A 
unique sequence VNSSN at a.a. 115-119.  Orange color highlights the Uev1A unique 
sequence PRAISV at a.a.125-130. 
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 were used in Western blot analysis against the five Mabs.  Figure 4-10 contains all Mms2 
and Uev1A full length and deletion contructs, including those shown in Figure 4-6.  
Figure 4-10 shows the Mab specificity for the three core Uev1Amutants.   Mab  LN1  has 
been characterized to bind only to the N-terminal region of Uev1A within a.a. 10-30.  
Mab LN1 was not expected to have  reactivity to any of the three core mutated Uev1A 
proteins and those expectations were proven correct.   Mabs LN2, LN2A and LN2B were 
of most interest when testing these constructs.  Following previous attempts to 
characterize these three core-specific Mabs, definative results characterizing the exact 
region of binding to Uev1A were not attained.  Figure 4-10 provides further verification 
that Mabs LN2 and LN2B do possess the same binding pattern to GST-Uev1A∆1-
30F104S and GST-Uev1A∆1-30+5.  These Mabs were found to compete with one 
another for binding to Uev1A in epitope mapping experiments as seen by their relative 
competition indicies in Table 4-3.  Furthermore, Mab LN2A is also a core binding Mab 
as is shown in Figure 4-6.  Mab LN2A does not compete with Mabs LN2 or LN2B for 
binding to Uev1A as shown in Table 4-3.  Additional proof of this Mab’s differential 
binding to the core is shown (Figure 4-10) in its absence of reactivity to GST-Uev1A∆1-
30F104S and GST-Uev1A∆1-30+5.  The lack of reactivity to GST-Uev1A∆1-30+6, in 
Figure 4-10, is  explained by a lack of overexpression.  Therefore, it is assumed that this 
protein was not present on the Western Blot and, therefore, there is  a lack of reactivity.   
 
4.8  Mab binding to Uev1B 
 Mabs LN1, LN2, LN2A, LN2B and LN3 were assayed for their binding 
phenotype to the Uev1B protein.  As mentioned before, Uev1B is a splicing variant of 
UEV1  that  has  the identical  Uev  domain  like  Uev1A, but contains distinct N-terminal 
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Figure 4-10.  Western blot analysis of each Mab with Uev1A-deletion and mutant 
constructs.  Uev1A-deletion and mutant contructs are used to analyze the binding 
specificity of the Uev1A unique core-specific Mabs LN2, LN2A and LN2B.  All six 
Western blots showed no primary antibody binding to GST-Uev1A∆1-30+6 as can be 
explained by a lack of overexpression.   
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sequences (Figure 4-5A).  The cellular function of Uev1B is not currently known. 
Although, it is known that Uev1B does not physically interact with Ubc13 (Andersen et 
al., 2005) and is excluded from the nucleus (P.L. Andersen, unpublished data).  Figure 4-
11 shows Mab reactivity of the GST antibody, Mab LN2 and Mab LN3 with GST-Uev1B 
as was expected.  Binding sequences previously determined for Mabs LN2 and LN3 are 
identical between Uev1A and Uev1B.  Mab LN1 does not show reactivity to GST-Uev1B 
as is expected due to its specificity to the N-terminal region of Uev1A. 
 
4.9 Mab LN1 binding to Uev1A in formalin-fixed paraffin-embedded tissue 
Mab LN1 is the only Mab which has been successfully used for Uev1A staining 
in formalin-fixed paraffin-embedded tissue samples.  Mabs LN2, LN2A, LN2B and LN3 
did not successfully stain in all tissues tested.  These results were obtained with the help 
of Dr. Emina Torlakovic of the Department of Pathology and Laboratory Medicine in the 
College of Medicine at the University of Saskatchewan.  Figure 4-12 illustrates 
cytoplasmic and nuclear Mab LN1 staining of Uev1A in normal thyroid cells.  Results 
show a loss of antibody binding when Mab LN1 is preabsorbed with the Uev1A purified 
protein.    Figure   4-13   shows   Mab   LN1    reactivity with Uev1A in gastrointestinal 
cancer tissues.  These tissue sections contain normal cells adjacent to the cancer cells, as 
indicated by the dashed line. Four of twenty 
adenocarcinomas of the gastrointestinal tract tested using immunohistochemistry were 
shown to have cytoplasmic and nuclear staining of Uev1A. Due to the heterogeneity of 
cancer tissues, four of twenty adenocarcinomas found to be postitive for Uev1A is 
considered to be a significant number.   In situ dysplastic/ mucosa with severe dysplasia, 
but no evidence of invasion, also showed overexpression in two of two cases, but to 
much lesser degree than in the invasive adenocarcinoma.  These results have indicated 
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that it would be valuable to perform additional research on normal versus cancer tissues 
to screen for Uev1A expression.   
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Figure 4-11.  Mab binding to GST-Uev1B, GST-Mms2 and GST-Uev1A.  Western 
blot analysis shows binding patterns of the three categories of Mabs isolated from the 
hybridoma screen to GST-Uev1B, GST-Mms2 and GST-Uev1A. 
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Figure 4-12.   Mab LN1 binding specificity to Uev1A in normal thyroid formalin-
fixed paraffin-embedded tissue.  A.  The negative control shows no staining in the 
cytoplasm or nuclei; the nuclei show blue color as a result of counterstaining with 
Haemotoxylin. B.  Immunohistochemistry was performed with Mab LN1.  Cytoplasmic 
staining was predominatly found. However, some variable staining of the nuclei was also 
observed. Note unstained cells in between the thyroid epithelium lining the follicles with 
thyrogolobulin, which support specific nature of the immunostaining by Uev1A Ab 
(arrows). Secreted thyroglobulin appears to show some weak non-specific staining (star).  
C.   As an internal control, Mab LN1 was preadsorbed with Uev1A antigen which 
resulted in total loss of cytoplasmic and nuclear reactivity to Uev1A. Some non-specific 
staining of the secreted thyroglobulin remained (asterisk). The bar represents 50 µm. 
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Figure 4-13. Mab LN1 binding specificity to Uev1A in normal and formalin-fixed 
paraffin-embedded carcinoma tissue. A.  Invasive adenocarcinomas of the 
gastrointestinal tract showed cytoplasmic overexpression of Uev1A.  Adjacent benign 
mucosa was present in this tissue sample and did not show Uev1A overexpression as 
indicated by the dashed line.  B. Neoplastic mucosa with severe dysplasia/carcinoma in 
situ also showed overexpression of Uev1A, but the expression appeared much weaker 
than in the invasive adenocarcinoma.  The bar represents 50 µm. 
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CHAPTER FIVE 
DISCUSSION 
 
5.1  Uev1A versus Mms2: sequence and structural implications for cellular function 
 The sequence and structural differences between the two Uevs, Uev1A and Mms2, 
must account for the distinct biological pathways by which they perform Lys63-linked 
polyubiquitination of cellular targets.  Both Uevs function alongside Ubc13 to create 
these non-canonical ubiquitin chains.  Obviously, the N-terminal Uev1A sequence of a.a. 
1-30 differs from Mms2.  However, the a.a. regions consisting of 104, 116-129 and 167-
169, which also differentiate Uev1A and Mms2, cannot be overlooked.  In fact, any of 
these regions of Uev1A may contribute to Uev1A’s differential cellular signaling 
function.  Epitopes may be as small as eight a.a. (Dreyer and Bennett, 1965).  Therefore, 
multiple epitopes may exist within the N-terminal region for which one Mab has been 
defined (LN1).  Additionally, examination of the core structure of Uev1A has revealed 
that F104 is situated adjacent to the seven variable residues within a.a. 116-129 as shown 
in Figure 4-9.  Three Mabs (LN2, LN2A and LN2B) have been characterized to bind the 
unique core of Uev1A within a.a. 110-130.  Many overlapping epitopes may exist in this 
unique region.  However, Mabs LN2 and LN2B are expected to bind the same epitope, 
based on results from EIA competition and Western blotting, and Mab LN2A is expected 
to bind to a different epitope than both Mabs LN2 and LN2B.  Essentially, three Mabs 
have been found to bind to at least two epitopes within the unique core region of Uev1A.  
The differences in a.a. sequence must be important for distinguishing Uev1A and 
Mms2 function. Due to the old age of the BALC/c female mice used for Uev1A 
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immunization and subsequent hybridoma fusions, it was expected to obtain antibodies to 
any region of the Uev1A protein.  See section 2.6 for further explanation in this regard.  
The C-terminal a.a. 167-169 differ from Uev1A to Mms2.  This is a region of the Uev1A 
that is located on the exteriorof the protein structure.  It is therefore expected that an 
antibody could have been generated to this region but, it was not obtained. One of the 
three Uev1A∆1-30 binding Mabs lost in the hyrbridoma screen may have bound to the 
Uev1A C-terminal region. However, it is also possible that the inbred BALB/c mice used 
for immunization were not capable of producing antibodies that would be specific to this 
putative epitope because they did not contain the genes necessary to do so.   
 The difference in the sequences of Uev1A and Mms2 are possibly important for 
interaction with an inhibitor or activator, or may be subject to covalent modification in 
order to alter the activity of Uev1A.  Additionally, another possible functional difference 
may arise for Uev1A if it performs auto-cleavage of its N-terminus for signaling or 
functional purposes.  Previously demonstrated experimental truncation of the N-terminus 
of Uev1A (Andersen et al., 2005) caused Uev1A localization to change within the cell 
when compared to full length Uev1A.  In fact, Uev1A∆1-30 and Mms2 were both shown 
to be localized to the nucleus following DNA damage treatment, whereas Uev1A was not 
(Andersen et al., 2005).   
 
5.2 Success in selecting Uev1A-specific Mabs 
 Many factors may have attributed to finally obtaining the Mabs of the desired 
Uev1A-specificity.  The timeline for immunizing BALB/c female mice, illustrated in 
Figure 3-3, may have played an important role in providing hyribdoma clones capable of 
binding the unique epitopes of Uev1A.  The mice used for hybridoma fusions were 
immunized five times.  Each mouse was administered 35 µg on the first immunization 
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and subsequently boosted four times with 17.5 µg.  These immunizations were 
administered over the period of one year prior to performing hybridoma fusions.  Firstly, 
it is believed that within this immunization timeline, antibodies of higher affinity and 
avidity would have been produced due to V(D)J recombination and hypermutation as 
discussed in Section 2-3.   Each immunization would provide B cells the opportunity to 
produce antibodies with increased affinity and avidity for the antigenic epitopes.  
Additionally, upon repeat immunizations there is a higher probability of obtaining 
antibodies of the IgG versus the IgM class (Uhr and Moller, 1968). 
 
5.3  Mab LN1: an N-terminal Uev1A-binding Mab 
Following selection of four Mabs capable of distinguishing Uev1A from Mms2, 
each Mab’s epitope specificity was assesed.  Mab LN1 was not the only initial putative 
N-terminal specific Mab.  Indeed, six putative Mabs capable of binding to Uev1A, but 
not Uev1A∆1-30 or Mms2 had been isolated.  However, through the screening process 
some Mabs either lost reactivity or were dropped from the screen due to being an IgM 
class.  Subsequently, Mab LN1 was the only N-terminal Uev1A-specific Mab 
successfully recloned and characterized.  Analysis of the binding pattern of Mab LN1 in 
both EIA and Western blotting was employed following the molecular cloning of deletion 
and a.a. substitution mutants of Uev1A.  Mab LN1 was found to bind Uev1A within a.a. 
10-30.   
Mab LN1 competition with Mab LN3 could prove to be a significant and valuable 
discovery.  Mab LN3 was found to be specific to the epitope containing a.a. 30-44 of 
Uev1A.  Consequently, Mab LN3 binds to the location near Asn37 and Phe38 residues 
which are necessary for Ubc13 binding to Uev1A.  Could Mab LN3 be employed to 
inhibit Ubc13 binding to Uev1A?  It is probable that an antibody may inhibit binding of 
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another protein.  However, the sequence from a.a. 30-44 of Uev1A is precisely the same 
as Mms2 and therefore Mab LN3 could not be used to differentiate Uev1A from Mms2 
for the purpose of inhibition.  Inhibiting the function of Mms2 could cause the demise of 
a cell’s genome stability.  For that reason, Mab LN3 cannot be used to specifically inhibt 
Uev1A-Ubc13.  However, Mab LN1 is capable of blocking Mab LN3 from binding to 
Uev1A. Thus, it may also be capable of blocking Ubc13 from binding Uev1A.  Indeed, 
without Ubc13 binding, Uev1A is unable to promote Lys63-linked polyubiquitin chains 
and NF-κB signaling could be abolished.   
Competition analysis showed Mabs LN1 and LN3 to compete for binding to 
Uev1A.  Due to their different sequence specificity in Western blot analysis (Figure 4-6), 
Mabs LN1 and LN3 must not compete for the same binding site, but rather block each 
other from binding to Uev1A at adjacent sites.  IgG antibodies have a MW of 150,000 
and HRP has a MW of 40,000.  HRP-IgG conjugation reactions are expected to yield 
three-four HRP molecules bound to one IgG molecule when allowed to bind at a 
mole/mole ratio.  A molecule the size of HRP-IgG could be from MW 270,000 to 
310,000.  Therefore, IgG at a MW of 150,000 may efficiently block binding of an HRP-
conjugated Mab at a MW of 270,000 to 310,000 to the same or adjacent binding sites on 
a protein with the folded structure of Uev1A, at a MW of 18,700.  The three-dimentional 
solution structure of Uev1A obtained through nuclear magnetic resonance technology has 
been presented in this thesis.  This structure permits investigation of the topography of 
the folded Uev1A protein.  Based on the Uev1A structure and the relative competition 
index values attained, it is clear that Mab LN1 binds an epitope of Uev1A which is more 
topographically accessible than the epitope for Mab LN3, as illustrated in Figure 5-1.  
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Figure 5-1.  Surface topography of Uev1A and putative binding epitopes of Mabs.  
Uev1A Mab LN1 is specific for the region of Uev1A from a.a. 10-30 designated in pink.  
Mab LN3 is specific for the region of Uev1A from a.a. 30-44 designated in green.  As 
can be observed from this image, Mab LN1 is able to bind to a more topographically 
accessible region of the protein and block the binding of Mab LN3 to a less accessible 
site. 
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Mab LN1 was the only Mab successfully used in immunohistochemistry staining 
of formalin-fixed paraffin embedded tissues.  Binding of Mab LN1 was observed in the 
cytoplasm and nucleus of normal thyroid tissue.  Interestingly, the core-specific Mabs 
LN2, LN2A and LN2B did not show any binding in these experiments. Previous 
experimentation has shown some Mabs are not useful for staining in fixed-tissue 
immunohistochemistry, while the same Mabs may be of use for staining fresh tissue 
sections (Torlakovic. E., personal communication). The reasoning for this is unknown. 
Nevertheless, Mabs LN2, LN2A and LN2B may be useful for fresh tissue staining.  
Another possibility for the lack of staining by Mabs LN2, LN2A and LN2B is that the 
unique core of Uev1A may be blocked by a covalent modification or protein binding to 
this region.  This would result in a condition whereby Mabs LN2, LN2A and LN2B could 
not bind to Uev1A in situ. 
 Assessment of Uev1A in SDS-PAGE shows two smaller MW bands (Figure 4-1).  
These lower MW bands may be naturally cleaved or truncated Uev1A molecules.  These 
bands were noted in the early stages of this Master’s research.  However, these low 
molecular weight protein bands were not sequenced due to the discovery of differential 
binding to these proteins by the Mabs obtained.  Mab LN1 appears to bind only to Uev1A 
and the middle MW band, whereas Mabs LN2, LN2A, LN2B and LN3 bind to all three 
protein bands.  The two smaller protein bands are expected to be approximately 155 and 
140 a.a based on migration in SDS-polyacrylamide gels.  As a result, it is presumed that 
there may be autocleavage of the Uev1A protein from the N-terminus. The Mab LN1 
binding specificity to only the larger two protein bands provides supporting evidence for 
this   as can   be observed in   Figure 4-4.  Furthermore, it   should   be noted here that the 
crystal structure of full length Uev1A could not be resolved.  Only when the N-terminal 
sequence was removed and a Uev1A∆1-30 construct was used could the crystal structure 
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be resolved (Moraes. T., personal communication).  Further investigation, using the 
formalin-fixed paraffin embedded tissues has only shown that Uev1A a.a 10-30 are 
present in these tissues.  At this time, it cannot be proven or disproven, whether other 
natural truncations of Uev1A may exist in vivo.  However, these observations may be of 
importance to further understand Uev1A functions. 
 
5.4  Mabs LN2, LN2A and LN2B: Unique core Uev1A-binding Mabs 
Mabs LN2, LN2A and LN2B were all found to be specific for the unique core 
region of Uev1A.  Six Mabs of this desired specificity were isolated in the initial Mab 
screening process.  Three were successfully recloned and characterized. Each core 
Uev1A-specific Mab was found to bind Uev1A, Uev1A∆1-10, Uev1A∆1-30, but not 
Uev1A∆1-30,∆110-130, Uev1A44 or Mms2 in EIA and Western blot.   Assesment of the 
core was needed for further analysis of the binding specificities of Mabs LN2, LN2A and 
LN2B.  Epitope mapping experiments revealed Mabs LN2 and LN2B to compete for the 
same or overlapping binding sites.  Mab LN2A did not compete with either Mab LN2 or 
LN2B.  Upon study of the NMR solution structure of the unique core region of Uev1A, 
three putative epitopes were defined as involving a.a 104, 115-119 and 125-130 as 
illustrated in Figure 4-9.  
This information lead to the creation of three Uev1A mutants involving these a.a. 
sequences.  By creating Uev1A protein constructs which contained core a.a substitutions, 
using the Mms2 sequence in place of the Uev1A sequence, it was expected that epitopes 
for each of the three Mabs could be ascertained by observing a loss of binding in Western 
blotting analysis.  Therefore, three Uev1A mutants were created as outlined in Sections 
3.1.1.3 and 4.6.  These constructs were named Uev1A∆1-30F104S, Uev1A∆1-30+5 and 
Uev1A∆1-30+6.  Uev1A∆1-30F104S contained a Phe-to-Ser mutation at a.a. 104, 
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Uev1A∆1-30+5 contained replacement at a.a. 115-119 of Uev1A by the Mms2 sequence 
INNSS and Uev1A∆1-30+6 contained replacement at a.a. 125-130 of Uev1A by the 
Mms2 sequence ARSIPV.   These constructs containing limited Mms2 sequences were 
expected to maintain a similar folded structure as Uev1A so as to not disrupt Mab 
binding to any a.a. region still present.  Also, these Mabs had previously been shown not 
to bind to these Mms2 a.a. sequences.  These constructs helped to show that, indeed, 
Mabs LN2 and LN2B bind to an epitope distinct from the epitope recognized by Mab 
LN2A.  Figure 4-10 shows Mabs LN2 and LN2B to bind Uev1A∆1-30F104S and 
Uev1A∆1-30+5, whereas Mab LN2A does not.  This data illustrates that Mabs LN2 and 
LN2B may bind to Uev1A a.a. 125-130 as they still bind to those proteins which contain 
this sequence, but have mutations in the other unique core sequences.  At this time, it 
cannot be proven that Mab LN2A binds to a.a. 115-119 as the protein Uev1A∆1-30+6 
was not blotted successfully due to a lack of expression.  However, Mab LN2A did not 
bind to Uev1A∆1-30F104S or Uev1A∆1-30+5 which does provide evidence of a 
differential binding pattern from Mabs LN2 and LN2B.   
Additionally, the Uev1A∆1-30 a.a. region from 125-130 was mutated at arginine 
126 to an alanine and overexpressed.  This R126A mutation was made because this 
arginine was found to be the most topographically accessible within the region from a.a. 
125-130.  However, following Western blotting analysis of this protein using Mabs LN1, 
LN2, LN2A, LN2B and LN3 it was found that all unique core binding Mabs bind 
Uev1A∆1-30R126A.  Therefore, Mabs LN2, LN2A and LN2B do not bind to an epitope 
dependent on arginine 126 of Uev1A (data not shown). 
 
 
 
 78
5.5  Future directions 
 In the immediate future, the Uev1A a.a. region from 124-130 should be mutated.  
Following investigation of the a.a. in this sequence, a Uev1A∆1-30 construct containing 
substitutions at a.a. 124 and 128 from the Uev1A to the Mms2 sequence should be cloned. 
These a.a. affect the topography of adjacent arginine and lysine a.a. which Uev1A and 
Mms2 share in common.  Subsequently, the differences in topography of the core 
epitopes are expected to depend on the a.a. at 124 and 128 of Uev1A. For example, 
Uev1A contains a serine at a.a. 128, whereas Mms2 contains a proline.  Therefore, due to 
the molecular structure of these two a.a., the proline may cause an adjacent common a.a. 
to be situated at a different angle than the serine.  Investigation of Uev1A lysine 132, 
which is common to Mms2, using the NMR solution structure, has shown that indeed this 
is the case.  As illustrated in Figure 5-2, the arginine and lysine residues of Uev1A are the 
most topographically accesible a.a. adjacent to the core unique a.a at 124 and 128. 
Therefore, a Uev1A epitope containing a.a. 124-132 is expected to be important for 
binding of Mabs LN2 and LN2B. Western blotting analysis with Uev1A∆1-
30P124A,S130P is expected to provide the final answer as to what the Uev1A binding 
epitope is for Mab LN2A.  
 In order to validate the usefulness of these Mabs in biochemical and medical 
research, obtaining knowledge of some additional properties of Mabs LN1, LN2, LN2A 
and LN2B is necessary.  In order to use the Uev1A-specific Mabs for diagnosis, the 
sensitivity  for  Uev1A  binding  in tissue   staining must be researched to obtain titers for 
use in further experiments.  Additionally, in order to understand any possible treatment 
potential for  the Uev1A-specific Mabs, the   ability to actually inhibit Uev1A function in 
vivo should be researched.  This would require delivery of Mabs LN1, LN2, LN2A or 
LN2B into living  cells in  order to  assay  for a loss of Uev1A function.  By asssaying the 
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Figure 5-2.  Comparison of the 3D structure of the core region of Uev1A from a.a. 
124-132 to that of Mms2.  NMR solution structure manipulations provide illustration 
and evidence of differential structure within the core a.a. from 124-132 of Uev1A when 
compared to corresponding a.a. in Mms2.  Yellow designates Uev1A a.a. R124 and 
Mms2 a.a. R106.  Blue designates Uev1A a.a. K132 and Mms2 a.a. K113.  Green 
designates Uev1A a.a. S129 and Mms2 a.a. P109.  Cyan designates Uev1A a.a. P125 and 
Mms2 a.a. A105.  The white star and arrow are present for the purpose of orientation.  
The white star designates a.a. S100 of Mms2 and S119 of Uev1A.  The arrow represents 
a.a. K134 of Mms2 and K154 of Uev1A. 
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ubiquitination status of NEMO or RIP1, blockage of function by Mabs LN1, LN2, LN2A 
or LN2B could be assessed.    After attaining these primary short term goals, these Mabs 
could be used for further characterization of the Uev1A-Ubc13 heterodimer and its 
function within living cells.  Additionally, further testing of cancer and noncancer tissues 
for overexpression of Uev1A may provide important insights for specific cancers.  In fact, 
one overexpressed isoform of Uev1A could well be indicative of tumorigenesis.  Mabs 
LN1, LN2, LN2A or LN2B may aid the discovery of this type of isoform-dependent 
Uev1A cancer signalling.  As such, it may be possible to use these Mabs as a dignostic 
tool to detect a specific Uev1A isoform or for cancer treatment if an inhibitory Mab-drug 
could be developed and administered to patients. Additionally, small peptipdes 
containing  the structure of an inhibitory Mab could be cloned following discovery of the 
Fab binding sequence and structure using mass spectrophotometry.  These could be 
potentially used as a method of treatment for Uev1A-related cancers. Some possibilities 
are discussed in Section 5.8. 
 
5.6 Applications and uses of Mabs 
 Milstein and Kohler won the Nobel prize in 1984 in physiology and medicine for 
their discovery of hybridoma technology because of its potential in laboratory 
experimentation, diagnostics and treatment. Mabs have become important for 
biochemistry, molecular biology and medicine.  Mabs are used in research in many 
experiments that require localization of antigens both in vitro and in vivo.  Mabs are 
useful for ascertaining biological functions of specific antigens through experimentation 
involving immunoprecipitations, Western blotting, enzyme immunoassays, 
immunofluorescence and immunohistochemistry. Mabs have also been used for 
diagnostics within the medical field.  For example, commercial tests for pregnancy look 
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for the presence of the beta subunit of human chorionic gonadotropin in urine using a 
Mab present on the test surface.  Additionally, medical laboratories can perform early 
diagnosis of the presence of pathogens involved in many diseases.   
One limitation of the early work in this antibody field was that, although Mabs are 
capable of targeting specific cell structures, most are not potent enough on their own to 
induce cell death.  Advances in technology to arm Mabs with cell-killing payloads have 
helped scientists overcome this constraint.  Technologies have been developed leading to 
an increase in the potency of Mabs, whether the antibody internalizes or stays on the 
surface of the targeted cell (Wu and Senter, 2005).  Subsequently, many Mabs have 
become useful for treatment of cancer and other diseases. 
 
5.7 Antibody-based cancer therapy 
To date, the federal drug administration has approved nine genetically engineered 
antibodies for the treatment of cancer.  Rituxan is a chimeric anti-CD20 antibody and the 
first antibody approved for immunotherapy in non-Hodgkin's B-cell lymphoma.  It is 
marketed by Genentech and Biogen IDEC (Plosker and Figgitt, 2003).  Herceptin, also 
marketed by Genentech, is a Mab that targets the HER-2 protein on the surface of breast 
cancer cells (Albanell et al., 2003).  Campath, marketed by Genzyme, targets the CD52 
antigen and is used to treat patients suffering from B-cell chronic lymphocytic leukemia 
(Alinari et al., 2007).  Erbitux, marketed by Imclone and Bristol-Myers Squibb for 
patients with colon cancer, is markedly specific for epidermal growth factor receptor 
(Wong, 2005).  Vectibix, for patients with colorectal cancer, targets epidermal growth 
factor receptor.  Bexxar and Zevalin are used for patients with non-Hodgkin's B-cell 
lymphoma and are specific for CD20.  Avastin, marketed by Genentech for patients with 
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colon cancer, targets the vascular endothelial growth factor (Carter, 2001; Kramer and 
Lipp, 2007). 
Antibody-drug conjugates (ADC) are an additional emerging therapeutic strategy 
for Mabs because they empower antibodies that have specificity for tumor cells, but no 
cell-killing capabilities. It is possible to deliver a potent, cytotoxic drug in a targeted 
manner to a tumor as compared to systemically injected drugs (Hamblett et al., 2004).  
Systemic administration of cytotoxic drugs is typically limited by toxicity resulting from 
exposure of normal tissues (Doronina et al., 2003).  By utilizing an ADC, it may be 
possible to achieve a higher concentration of drug at the tumor while minimizing 
exposure to normal tissues.  The federal drug administrataion approved the first ADC for 
cancer, Mylotarg®, in 2000.  Mylotarg, marketed by Wyeth, links an antibody with the 
drug calicheamicin (Ricart and Tolcher, 2007), which is an enediyne class of antitumor 
antibiotic that binds to DNA and induces apoptosis.  This treatment is used for patients 
with acute myeloid leukemia. 
Therapeutic applications of Mabs are widespread.  Although they have been used 
for some cancer therapies, not all cancers have been ‘cured’.  Cancer is genetically based 
disease.  Many tumor suppressor genes may lose function and oncogenes may gain 
function with mutations caused by carcinogens, resulting in tumorigenesis.  Some cancers 
have treatments available, but many do not.  Mabs have proved to be a useful tool and in 
years to come there may be many more federal drug administration-approved Mab-based 
drugs. 
 
5.8 Research, diagnostic and treatment potential for Uev1A-specific Mabs 
 The research potential of these Mabs may be widespread based on their usefulness 
in many experiments as previously mentioned in Section 5.6.  It is interesting to note that 
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Mabs specific for Ubc13 and Uev1A/Mms2 have been raised in Dr. Wei Xiao’s research 
laboratory.  These Mabs have been licenced to Invitrogen and Santa Cruz by the 
University of Saskatchewan.   Mabs LN1, LN2, LN2A and LN2B should be considered 
even more valuable as they differentiate between Uev1A and Mms2.  Therefore, there is 
expected to be considerable research potential for Mabs LN1, LN2, LN2A and LN2B.  
The treatment potential of each of Mabs LN1, LN2, LN2A and LN2B is unknown 
at present.  Firstly, the Mab must have the ability to specifically recognize Uev1A.  The 
results presented here prove this goal has been reached.  Secondly, the Mab would need 
to be humanized, or made into a chimera to prevent the Human Anti-Mouse Antibody 
(HAMA) response.  Initial clinical studies found Mabs to be of limited therapeutic value, 
because early mouse-derived Mabs often resulted in an immune system response by 
patients. When injected into humans, a mouse Mab is usually recognized by the body’s 
immune system as being foreign.  The human immune system therefore responds by 
rapidly neutralizing the mouse Mab and rendering it ineffective for further therapy, a 
reaction referred to as a HAMA response (Thorpe et al., 2003).  Over the past three 
decades, researchers have developed a number of approaches to make mouse Mabs 
appear more human-like to a patient’s immune system, thereby lowering the risk of 
inducing an immune response.  These technologies have enabled scientists to develop 
antibody products that can be administered to patients repeatedly over time with reduced 
adverse responses by the human immune system.  A therapeutic Mab can be chimeric, 
humanized or fully human (Neuberger et al., 1985).  A chimeric Mab contains a mixture 
of both mouse and human sequences, usually a 30/70 split, respectively, where the mouse 
components are responsible for binding to the antigen and the human components are 
involved in inducing a therapeutic effect.  Humanized Mabs contain over 90 percent 
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human sequences, while fully-human Mabs contain 100 percent human sequences 
(O'Kennedy and Roben, 1991). 
Thirdly, the Mab would need to have a drug conjugated that would induce 
apoptosis of target cancer cells.  As mentioned above, calicheamicin can be used as a 
potent cell-killing agent.   How would a Mab be linked to calicheamicin and specifically 
target cancer cells if the overexpressed cancer causing antigen is inside the cell?  
Calicheamicin is a potent cytotoxic agent that causes double-strand DNA breaks, 
resulting in cell death.  If this chemical was linked to any of the Mabs reported in this 
thesis, many issues may arise.  For example, a calicheamicin-linked Mab LN1, LN2, 
LN2A or LN2B would not be able to recognize the exterior of the cancer cells, and 
acquire access to the inside of the cell.  But it would be necessary to target cancer cells on 
the exterior before any killing action is taken as Uev1A is found in all eukaryotic cells. 
This would be crucial to reducing total cell killing.  Therefore, it is not feasible that 
recognition of Uev1A and cleavage of the linked calicheamicin could kill cancer cells 
alone.  How would a therapy that would use Uev1A-specific Mabs specifically target 
cancer cells?   One possibitity would be to link a Uev1A-specific Mab to calicheamicin 
and another cancer cell surface-specific molecule.  But in that case, would the Uev1A-
specific Mab add any killing potential or is the cancer cell surface binding molecule of 
more therapeutic value?  Uev1A-specific Mabs may be of potential value for escalating 
the explicit cell killing from the inside of a cancer cell if employed with a linked cell-
killing agent and cancer cell surface-specific molecule. In this way, the exterior of a 
cancer cell would be differentiated by the cell surface-specific linked molecule, would be 
taken up by the cancer cell and once bound to Uev1A, calicheamicin would be released to 
kill the cells.   However, it remains uncertain at this time as to whether the Uev1A-
specific Mabs will be useful for cancer therapeutics. 
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5.9  Significance of these research findings 
 The development and characteriation of four Uev1A-specific Mabs (LN1, LN2, 
LN2A and LN2B)  and one Uev1A-nonspecific Mab (LN3) will allow research labs to 
employ molecular and biochemical techniques in order to discover novel findings with 
respect to Uev1A function in eukaryotic cells.  To date, these Uev1A-specific Mabs are 
the only reagents known to differentiate Uev1A from Mms2 in the world.  The overall 
implications of these Uev1A-specific Mabs are unknown at this time.  However, the 
potential uses for them  may be widespread from research and diagnostics in a laboratory 
to potential anti-cancer pharmaceuticals.   
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APPENDIX A- Solutions, buffers and media 
 
 
6.1 Chemicals, media and reagents 
 
Agarose gel 0.6% agarose in 1X TAE buffer  
 
Alkaline phosphatase buffer 100 mM Tris, 100 mM NaCl, 5 mM MgCl2, 
pH 9.5 
 
Alpha calf bovine immunoglobulin  
depleted serum Gibco, 200-6200-AJ 
 
Blocking solution    PBST, 5% non-fat milk powder 
 
Bovine albumin Sigma, #A-7906 
 
5-bromo-4-chloro-3-indolyl phosphate  Bio-Rad, #170-6539 
 
Calf supreme bovine immunoglobulin  
Serum Hyclone, #A-2161-L 
 
Cleavage buffer 50 mM Tris-amino, 100 mM NaCl, 1 mM 
EDTA, pH 8.0 
 
Coomassie blue stain 0.025% Coomassie Brilliant Blue R250, 
40% methanol, 7% acetic acid 
 
Copper sulphate    VWR international 
 
Cytoseal mounting medium   Richard Allen Scientific, #8310-16 
 
diaminobenzidine  Envison Plus HRP Kit, Dako #K4007 
De-stain solution    40% methanol, 10% acetic acid 
 
 
EIA assay diluent 1X PBS, 2% Tween 20, 2% bovine albumin, 
2 mM merthiolate 
 
Envision Dako Kit     Dako #K4007 
 
Ethanol     VWR international 
 
Ethidium bromide    Sigma, #E8751 
 
Goat-Anti-GST Antibody   GE healthcare, #27-4577-01 
 
Goat-Anti-Mouse IgG, H & L  
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Alkaline Phosphatase Conjugated  Calbiochem, #401212 
 
Glutathione elution buffer  10 mM glutathione in 50 mM Tris-HCl, pH 
8.0 
 
HAT Boehringer mannheim 
 
Haematoxlin 1 Richard Allen Scientific, 8310-10 
 
Hydrogen peroxide VWR international 
 
 
Immunhistochemistry antibody-  
dilution buffer Dako, #S3O22, (0.05 mol/L Tris-HCl, 0.1% 
Tween, 0.015 mol/L sodium azide). 
 
Luria broth 1% Bacto-tryptone, 0.5% Bacto-yeast 
extract, 1% NaCl, pH 7.0 
 
Luria agar     US Biological, #L1500   
   
Methanol     VWR international 
 
nitroblue tetrazolium chloride   Bio-Rad, #170-6532 
 
PBST      PBS, 0.05%Tween20  
 
PEG 1500 in 75mM Hepes Boehringer mannheim 
 
Phosphate buffered saline  140 mM NaCl, 2.7 mM KCl, 10 mM 
Na2HPO4, 1.8 mM KH2PO4, pH 7.3 
 
Protein sample buffer 125 mM Tris pH 6.8, 4% SDS, 10% 
glycerol, 0.006% bromophenol blue, 1.8% 
β-mercaptoethanol 
 
PVDF membranes Perkin-Elmer, #NEF1002 
 
Rabbitt-Anti-Goat IgG, H & L 
Chain alkaline phosphatase conjugated Calbiochem, #401512 
 
RPMI 1640 S-O media (serum free) RPMI 1640 
 
RPMI 1640 S-10 media RPMI 1640, 0.1% mercaptoethanol, 0.01% 
NaSel, 5% calf supreme bovine 
immunoglobulin serum and 5% alpha calf 
bovine immunoglobulin depleted serum 
(heat inactivated), 0.01% gentamicin 
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RPMI 1640 HT media RPMI 1640, 0.1% mercaptoethanol, 0.01% 
NaSel, 5% calf supreme bovine 
immunoglobulin serum and 5% alpha calf 
bovine immunoglobulin depleted serum 
(heat inactivated), 0.01% gentamicin, and 
HT 
 
RPMI 1640 HAT media RPMI 1640, 0.1% mercaptoethanol, 0.01% 
NaSel, 5% calf supreme bovine 
immunoglobulin serum and 5% alpha calf 
bovine immunoglobulin depleted serum 
(heat inactivated), 0.01% gentamicin, and 
HAT 
 
SOC  2% Bactro-tryptone, 0.5% Bacto-yeast 
extract, 0.05% NaCl, 20 mM glucose, 2.5 
mM KCl, 10 mM MgCl2, pH 7.0 
 
TAE buffer 24% Tris base, 5.7% glacial acetic acid, 
10% EDTA, pH 8.0  
 
Transfer buffer 0.037% SDS, 5.8% Tris-base, 3% (w/v) 
glycine, 10% methanol  
 
Xylene      VWR international 
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APPENDIX B –Suppliers 
 
7.1 Antibodies, plasmids, DNA and cell lines 
 
Antibodies used in EIAs: 
 
HRP-conjugated affinity-purified 
goat anti-mouse H-chain-specific IgG1 Southern Biotechnology Associates Inc. 
   
HRP-conjugated affinity-purified 
goat anti-mouse H-chain-specific IgG2a Southern Biotechnology Associates Inc. 
   
HRP-conjugated affinity-purified 
goat anti-mouse H-chain-specific IgG2b Southern Biotechnology Associates Inc. 
   
HRP-conjugated affinity-purified 
goat anti-mouse H-chain-specific IgG3 Southern Biotechnology Associates Inc. 
   
HRP-conjugated affinity-purified 
goat anti-mouse H-chain-specific IgM Southern Biotechnology Associates Inc. 
 
HRP-conjugated AffiniPure    
goat anti-mouse IgG + IgM 
(H + L chain-specific)   Jackson ImmunoResearch Labs  
  
   
AffiniPure goat anti-mouse IgG + IgM  
(H +L chain-specific) minimum cross 
reaction to human, bovine and horse 
serum proteins     Jackson ImmunoResearch Labs 
      
  Antibodies were supplied by Dr. Barry Ziola 
 
BL21-CodonPlus (DE3)-RIL   Stratagene, #230245 
cDNA clones of MMS2   Dr. Wei Xiao 
 
cDNA clones of UEV1A Z.J. Chen, university of Texas Southwestern 
Medical Center, Dallas, TX 
 
cDNA clones of UEV1B S. Lin, Robert Wood Johnson Medical 
School, Piscataway, NJ 
 
Escherichia coli DH10B  GibcoBRL (now Invitrogen) 
pGEX-6P  GE Healthcare, #27-4597-01 
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PCR primers  IDT, each sequence custom made 
 
7.2 Equipment and supplies 
Amicon Ultra centrifugal 54 filter devices Millipore, #901024 
Avanti Beckman centrifuge   Beckman-Coulture, #SJ-1M-1 
 
BCA Protein Assay Kit  Pierce, #23227 
Biosafety cabinet  Caltec Scientific, #BM4-2A-49 
EIA reader  Bio-Rad, #2550 
Envision Dako Kit     Dako, #K4007 
 
Gene Pulser Cuvette    Bio-Rad, #165-2089 
 
GSTrap column (5ml)    GE Healthcare, #17-5131-01 
 
Hydration chambers Scientific Device Laboratories, #197BL 
 
Immulon 4 flat bottomed plates Dynatech Labortories Inc, #001-010-3850 
 
Mini-Protean 3 gel apparatus   Bio-Rad, #165-3301 
Prescission Protease    GE Healthcare, #27-0843-01  
 
PTC-100 PCR     MJ Research, Inc., Watertown, MA 
 
150 cm2 tissue culture flask   Corning, #25120 
 
TMB microwell peroxidase substrate  KPL, #50-76-00 
 
UV Transilluminator  Fisher Biotech, #FBTIV-614 
 
7.3 Computer programs 
 
MacReader 2.0 Software   Bio-Rad  
 
PyMOL version 0.96     DeLano Scientific  
 
 
 
 
